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1 Introduction 
1.1 Childhood asthma  
Asthma is a complex chronic pulmonary disease with four main pathogenetic 
properties: airway hyperresponsiveness (AHR), bronchial obstruction, airway 
inflammation and airway remodelling. It is the result of a complex interaction involving 
the respiratory tract, inflammatory cells, cytokines and other mediators [1]. A variety 
of influences from (epi-)genetic background to environmental exposure as well as 
respiratory tract infections have been shown to influence the pathogenesis of asthma 
[2-4]. While asthma affects patients of every age, its pathogenetic origins most likely 
lie in the early stages of life [5]. Subsequently, asthma is considered to be the most 
common chronic disease in childhood. Prevalence is continually increasing and 
varies between 5-20% in 13- to 14-year-old children in different parts of the world [6-
8]. In younger patients, especially preschool children, making a reliable asthma 
diagnosis has proven to be a challenge, though not impossible, as obtaining 
objective lung function measurements is difficult and airway inflammation as an 
important criterion has been poorly studied in preschool children [9]. As the most 
frequent asthma-related symptom in paediatric patients is wheezing, a high-pitched 
whistling sound during expiration, wheeze - and not asthma - is the term mainly used 
to describe the illness in this group [10, 11]. The prevalence of wheeze is high as 
almost every third child will experience wheeze at least once until school age, with 
recurrent wheeze affecting roughly 8% to 20% of children [12-15]. 
 
However, wheeze as a pulmonary symptom is not automatically equivalent to an 
actual diagnosis of asthma, while not all asthma patients necessarily show wheezing 
[16]. This makes for a challenging process of correctly differentiating and then 
treating these groups which are very heterogenous in clinical presentation, progress 
and response to therapy [6, 17, 18].  
Current treatment guidelines, such as the 2018 GINA (global initiative for asthma) 
guidelines, mainly propose age-adjusted treatment steps according to the level of 
disease severity as well as symptom control, with varying priorities on different 
medications such as steroids and 2-agonists, only just beginning to implement more 
individualized approaches [19-24]. This might be one reason for the varying response 
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to pharmacological therapy, accounting for patients with mild asthma who still have 
substantial residual disease and some patients with severe asthma who are 
classified as non-responders [25-27]. Non-responders are patients suffering from 
severe or uncontrolled asthma even under medication, a group that is especially 
relevant in preschool children under four years of age [28]. Not only do these children 
suffer a greater loss of quality of life, but some additionally propose a possibly 
increased risk of developing COPD (chronic obstructive pulmonary disease), a 
disease with features similar to asthma but characterized by irreversible airflow 
obstruction, in the third or fourth decade of their life [29]. As asthma cannot be cured 
at the moment, effective therapy will be the key to limit this substantial risk, relieve 
health care costs and, most of all, to increase the patients’ quality of life [30-32].  
 
In summary, childhood asthma, despite all efforts, continues to impose a 
considerable burden on paediatric patients as well as on health care systems [33, 
34].  Disease prevention as well as the access to adequate therapy remain limited for 
many children as long as especially the underlying pathogenetic mechanisms of 
asthma are incompletely understood. 
A recent, promising theory about asthma pathogenesis is the view of asthma as a 
complex disease. This term describes a condition in which a mild genetic hit can 
have a major impact on the clinical presentation when acting together with 
environmental factors, integrating the two main known pathogenetic pathways as well 
as the emerging clinical view of asthma as a syndrome [35]. This new understanding 
lays the foundation for a more precise classification of patients into clinical 
phenotypes as well as biological endotypes, which will be the first step on the way to 
more individually tailored care for patients with childhood asthma, supported by 
biomarkers1 used to improve diagnostic processes and disease monitoring [26, 36].  
As a long term goal, especially patients suffering from severe or poorly controlled 
asthma would benefit from more effective therapies and maybe even possible cures, 
developed and delivered to precisely defined patient subgroups with the help of 
biomarkers [37-39].  
 
 
1 Biomarkers are indicators of physiological or pathogenetic processes, or even of a response to a 
therapeutic intervention, that can be objectively measured and evaluated. 
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1.2 Phenotyping 
1.2.1 Clinical phenotypes 
In clinical practice, phenotypes define groups of patients presenting a similar 
combination of symptoms. There are several ways to define those phenotypes, two 
of the most commonly used being a clinical and an epidemiological approach [40].  
For preschool children, the most frequently used approach is based on clinical 
criteria and takes the patient’s history, diagnostic techniques and treatment 
responses into account. Following this system, children with preschool wheeze are 
classified in two subgroups and then treated accordingly: Either multi-triggered 
wheeze (defined as wheeze being caused by at least two of the following six criteria: 
cold, effort, dust, animal contact, grass pollen, or others) or episodic viral wheeze, in 
which wheeze typically occurs during distinct episodes of respiratory viral infection, 
mainly with rhinoviridae [13, 17, 41-44].  
However, data about the prevalence and, even more important, about the reliability of 
these phenotypes have only been published recently. For example, van Wonderen et 
al. showed in a cohort study that stable multitrigger and episodic viral wheeze are 
relatively uncommon as about 80% of the children changed phenotypes in the period 
of 24 months [45]. In accordance, there have also been reports about significantly 
varying prevalence between wheeze and asthma, which renders the current use of 
wheeze as a proxy symptom for asthma problematic [16].  Additionally, the clinical 
approach is based on the paediatrician’s subjective perception of child and wheeze in 
a particular, not necessarily representative moment. Thus, perception and labelling of 
wheeze symptoms often varies among paediatricians and other clinicians, 
diminishing its reliability considerably [37, 40, 46].  
These limitations cause a serious problem in separating preschool children with self-
limiting episodic viral wheeze from children who will continue to experience 
symptoms and eventually receive an asthma diagnosis. However, this differentiation 
is crucial because one does neither want to submit a child to unnecessary therapy 
not withhold necessary therapy from a child that needs it as early as possible in order 
to limit long-term complications and alleviate overall morbidity [14, 47].  
 
In children older than six years, the most common clinical phenotype distinction is 
mainly based on IgE, an immunoglobulin used to measure allergic sensitization. This 
results in a group of patients classified as allergic asthmatics, who present a high 
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level of IgE (and in particular a positive specific IgE for the most common 
aeroallergens in combination with characteristic clinical symptoms) as well as 
pulmonary symptoms like wheezing, coughing, or an impairment of lung function. As 
there is specific therapy available in the form of anti-IgE-antibodies, the classification 
as allergic asthma has a direct impact on treatment. Meanwhile, a low level and/or 
negative specific IgE without any allergy-related clinical symptoms is what defines 
the non-allergic phenotype [48].  
However, the roles of atopy and IgE as a potential biomarker are under re-evaluation 
especially in younger patients, as atopy takes time to manifest and a clear causal 
connection to asthma pathogenesis has never been proven, suggesting an influence 
of other factors like viral infections [38, 49, 50]. Subsequently, recent studies about 
the use of IgE in prediction of response to omalizumab (an anti-IgE antibody) left the 
role of IgE as a specific biomarker increasingly unclear [50]. More promising results 
were obtained when using the count of blood eosinophils, which is usually elevated in 
asthma [51].  
Even so, these results are still not satisfying, suggesting that the dichotomy of 
allergic versus non-allergic asthma (and in parallel terms, multitrigger wheeze and 
episodic viral wheeze) does not do the disease’s heterogeneity justice. Instead, there 
has been a change towards looking for other methods to define phenotypes, 
ultimately combined in the approach of endotyping that will be explained later on, in 
the hope of a better prediction of treatment responses and outcome as well as the 
development of individualized therapeutic options [36]. 
 
1.2.2 Epidemiological phenotypes  
Another approach to phenotyping is based on epidemiology and driven by data 
stemming from birth cohorts. Mainly latent class analysis (LCA) is used to define 
groups with similar features in a larger heterogeneous group of subjects. As it 
traditionally refers to longitudinal data, it focuses on longitudinal time patterns. This 
way of phenotyping results in longitudinal time patterns and the subsequent 
phenotypes are defined as early transient, persistent or late-onset wheeze as 
illustrated below [17, 18]. 
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Figure 1: Course of longitudinally defined phenotypes. Modified after [52].  
However, as it can only be performed in retrospective, this method is most commonly 
used for research purposes. For example, early transient wheeze is defined as the 
patient having started to wheeze before three years of age but stopped around three 
years, which can only be said in retrospect, and is thus not applicable for clinical 
management of a patient [13, 38].  
Recent efforts to combine both the clinical and the epidemiological approach in order 
to gain benefits from both have found some cases in which the clinical phenotypes 
match the LCA phenotypes, as for example in multitrigger wheeze and persistent 
wheeze, respectively. While this is promising, in other cases they differ greatly, 
further stressing the need to combine more methods for additional precision [17, 18]. 
In an effort to include the change in clinical picture over time, which is common 
especially in children, a recent study by Gardner et al. tried a new approach to 
increase both reliability and stability in connecting LCA phenotypes defined at 
different time points through transition probabilities. Parallel to the above, they found 
evidence supporting some but not all clinical phenotypes [53].  
A possible way to increase their accordance and subsequently, to define more 
precise and thus more reliable phenotypes could be gaining more in-depth insights 
into the underlying pathogenetic immune mechanisms and taking them into account 
when merging the clinical and epidemiological approach to phenotyping. 
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 6 
 
1.3 Immunological mechanisms in the pathogenesis of asthma 
An understanding of the complex underlying mechanisms of the immune system is 
needed prior to integrating immunological insights in the definition of asthma 
phenotypes. The following chapter will comprise a short summary of known 
mechanisms important for asthma pathogenesis in innate and adaptive immunity. 
1.3.1 Adaptive immunity 
In general, adaptive immunity can be divided in T-cell immunity and B-cell immunity. 
B-cells are mainly responsible for the humoral part of adaptive immunity as they 
produce highly specific antibodies. T-cells are further classified into CD8+-T-cells with 
cytotoxic function and CD4+-T-cells with their multiple subsets (see figure 3 below). 
Any kind of adaptive immune response requires the T-cell receptor (TCR) to 
recognize antigen fragments presented via major histocompatibility complex (MHC) I 
or II, depending on the cell type, on antigen presenting cells (APC). This crucial 
pathway is regulated through expression patterns of pattern recognition receptors 
(PRR) on epithelial cells (EC) and APCs. This seems to play a role not only in allergic 
sensitization but also in ongoing asthma [54, 55]. 
MHCI is expressed on all nucleated cells in the body, while the coreceptor necessary 
for antigen presentation, CD8, is only expressed on CD8+ T-cells. Via MHCI, 
cytoplasmatic proteins are presented, which in physiological circumstances induces 
self-tolerance from natural killer cells. In case of intracellular, viral infection highly 
specific, cytotoxic CD8+ T-cells are activated to eliminate the pathogen.  
Antiviral immunity in particular has long been of interest for asthma pathogenesis, as 
epidemiologic studies have shown respiratory viral infection to be an independent 
risk factor. The exact pathophysiological mechanisms through which viral infection 
influences asthma development are still to be elucidated, but an altered immune 
response to viral infection seems to be an important factor. For example, respiratory 
syncytical virus, a very common infection in small children, is thought to 
overstimulate a Th2-type response, which in turn is associated with allergy and 
asthma development as explained in the following [56, 57]. Antiviral immunity is also 
a good example of how asthma is a disease featuring the adaptive as well as the 
innate immune system. There are many intersections through which both systems 
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communicate and influence each other, physiologically maintaining a fine balance 
between inducing and resolving inflammation [26, 58]. 
 
In contrast, MHCII is only expressed on myeloic cells with the capacity to present 
antigens, like dentritic cells (DC), macrophages and also B-cells as well as ECs. On 
MHCII, fragments of extracellular antigens that have been taken up and processed 
by antigen-presenting cells are presented to naïve CD4+ T-cells, also called T-helper 
cells, in the lymph nodes draining e.g. the lungs [59, 60]. 
 
 
Figure 2: Overview of differentiation pathways from progenitor cells for cells of the immune system. 
Peripheral T-cell subsets also include Th19-cells and Th22-cells (not shown), from [61].  
 
In the past, the main role of adaptive immunity for asthma has often been limited to 
the role of the T-helper-Cells (Th-cells). Th1-type cells mainly produce IL-2 and IFN-γ, 
which, in high doses, have suppressive capacities on activated B-cells, which is 
important for terminating an immune response. Additionally, they can activate 
macrophages, resulting in cytotoxicity, which makes them an effective weapon 
against for example acute viral infection.  
Th2-type cells, more prominent in chronic inflammation, produce interleukins (IL) IL-4, 
IL-5 and IL-13, helping B-cell dependent humoral immunity in the production of 
immunoglobulins (Ig) like IgE. IgE is an antibody strongly linked to allergy as it can 
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lead to histamine release from mast cells when cross-linked to the Fcε -receptor on 
mast cells. Reinforcing the relation to allergy, Th2-cells induce mucosal mast cell 
proliferation (mainly via IL-4) as well as proliferation of eosinophils (mainly via IL-5), 
both cell types activated by IgE. Physiologically, these mechanisms are at least partly 
suppressed by Th1-type cells [59].  
In previous asthma research, the “Th2-hypothesis” links the typical symptoms of 
allergic asthma to an imbalance between a diminished Th1-type answer and a 
heightened Th2-type response, leading to IgE production, histamine signalling and 
then airway inflammation [54]. This Th2-shift is especially prominent in the neonatal 
immune system, a time thought to be crucial for asthma development [62]. 
Additionally, Th2-type cytokines have been found to be increased in asthmatic 
children. APCs might at least partly at fault for this disequilibrium as they are 
responsible for the presentation of allergens in mucosal surfaces and start the 
immune response leading to allergy in the genetically susceptible individual [59, 63].  
 
As the view of asthma evolves, the Th2-hypothesis has lost influence in favour of an 
immunological response that is as heterogenous as the disease with many different 
contributing pathogenetic mechanisms [64]. For example, the involvement of other 
Th-cell subtypes has been shown, such as Th17-cells, which are said to drive 
neutrophilic and macrophage inflammation in non-allergic asthma [54, 65].  
IL-17, the cytokine produced by this Th-cell subset, counteracts the anti-inflammatory 
properties of another Th-cell subset, the Th-regulatory cells (Treg) [66]. Lluis et al. 
showed this reciprocal regulation in a cord blood study and proposed that early 
immune maturation of Th17-cells depends for example on genetic predisposition 
among other factors [67]. In studies investigating protective factors, maternal farming 
has been found to positively influence both Treg count and function [68]. 
Consistently, Tregs have been identified to have an overall immuno-supressive 
function. However, they have also been shown to be enriched in children with allergic 
asthma, which could indicate a counter-regulatory process [2]. 
1.3.2 Innate immunity 
As it becomes increasingly clear that childhood asthma has its roots in the earliest 
stages of life, the role of innate immunity has shifted into focus. The reasoning 
behind this is that as adaptive immunity takes time to mature to its full capacity, the 
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innate immune system is very prominent especially at the beginning of life and thus 
in the period seen as critical for asthma development [5].  
Innate immunity is the human body’s first line of defense against pathogens such as 
fungi, bacteria and viruses as well as a variety of altered cells like apoptotic, 
degenerated and virally infected cells. Its task is to recognize these structures as 
antigens (i.e. any structure that eventually leads the immune system to produce 
antibodies) and, in case of pathogens, to signal the adaptive immune system an 
infection has occurred. 
Its cell types, as illustrated below, can be divided into primarily antigen-presenting 
cells like dendritic cells and primary killer cells, like macrophages, neutrophilic 
granulocytes and natural killer cells. In contrast to the adaptive system, there is no 
memory function in innate immunity.  
 
 
Figure 3: Cell types of innate and adaptive immunity. Each system consists of a cellular part and a 
humoral part (complement protein or antibodies, respectively). At the interface of adaptive and innate 
system, see natural killer cells and γδ T-cells, both cytotoxic lymphocytes. From [69]. 
The pathogen receptors of the innate immune system are called pattern recognition 
receptors (PRR) and recognize pathogen associated molecular patterns (PAMPs), 
conserved molecular motifs shared by a class of microbes, which are relatively 
unspecific. They are highly conserved in evolution and commonly divided into four 
subgroups: Toll-Like receptors (TLR), C-Type Lectin receptors (CLR), RIG-I-like 
receptors (RLR) and Node-like receptors (NLR).  
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Upon ligand binding, a complex signalling cascade leads to the typical features of 
innate response: generation of ROS (reactive oxygen species), activation of the 
arachidonic acid cascade, an increase of intracellular calcium, and the activation of 
the mitogen-activated protein kinase (MAPK)-pathway, which influences transcription 
factors such as e.g. NFκB (nuclear factor 'kappa-light-chain-enhancer' of activated B-
cells) and NFAT (nuclear factor of activated T-cells). Both transcription factors are 
found in almost all immune cells, in the innate as well as in the adaptive system. 
Functioning and activation of NFkB and NFAT are largely dependent on Ca2+ related 
mechanisms. Their targets for enhanced transcription include signalling proteins, cell 
surface proteins, other transscription factors and also cytokines like IL1, IL-18 and 
IL-8 [70-72].  
Additionally, PRRs also recognize endogenous damage-associated molecular 
patterns (DAMPs), which occur e.g. when tissue is damaged by ongoing 
inflammation. Physiologically, macrophages eliminate them in order to limit immune 
activation, preventing excess inflammation [26]. 
Many of the innate immune system’s cell types - including monocytes, lung-specific 
macrophages, natural killer cells (NK), dendritic cells, neutrophils, mast cells and 
eosinophils have been shown to be enriched in asthma patients [73].  
In particular, dendritic cells are vitally important innate immunity cells as they do not 
only express the most PRRs, but they also orchestrate immune response following 
their activation. They, like other immune cells, produce different mediators, like IL1β 
and histamine, which is an important cytokine in allergic reactions. Through these 
mediators, they can also influence the adaptive system (and vice versa), for example 
in the pathogenesis of allergy [73, 74]. Recently, another cell subtype, innate 
lymphoid cells, has also been proposed to be involved in allergic sensitization and 
inflammation, linking innate to adaptive immunity [75, 76]. 
Furthermore, innate immunity is also represented by epithelial cells in the airways, 
which act as sentinels and express innate receptors in the same manner as 
professional antigen presenting cells like DCs [55, 73].  
 
Undoubtedly, airway inflammation and subsequent airway remodelling are main 
features of asthma and most likely contribute to its other known features such as 
airway hyperreagibility [1]. Changes in the regulation of the innate immune system 
are likely to contribute to the pathogenesis of asthma in many ways. For example, 
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Boeck et al. showed a link between innate antiviral immunity and asthma 
manifestation through distinct differences for the expression of innate immunity 
antiviral receptors such as LY75, as well as other genes related to calcium signalling,  
in children with allergic as well as non-allergic asthma [77]. Other studies 
investigating the connection of innate immunity and childhood asthma show 
increased neutrophilic inflammation levels for children with non-allergic asthma and 
decreased innate immunity-related gene expression for children with allergic asthma 
[78]. As the lungs constitute an important immunity barrier to the outside world, an 
altered antiviral immunity early in life, and thus in the vulnerable period, might lead to 
excess inflammation and subsequent airway remodelling, finally facilitating the 
development of asthma [5, 62].  
 
1.4 Endotyping 
The effort to integrate immunological insights into the definition of asthma 
phenotypes has led to the definition of the term endotype, describing a specific 
pattern of pathogenetic mechanisms and/or treatment responses leading to a specific 
clinical presentation of asthma [26, 79]. Adding another level of complexity, different 
endotypes could present as the same phenotype [80]. 
Parallel to the growing acceptance for the existence of endotypes, another paradigm 
shift to looking at asthma as a syndrome rather than as a multi-faceted disease might 
allow for more individualised therapy. This definition of an “asthma-syndrome” 
consists of wheeze phenotypes, each of them with their own distinct endotypes, 
including specific immunological patterns and environmental factors [2, 40, 54, 81]. 
With this new key hypothesis, the vast amount of clinical and research data can be 
organized in order to explain the heterogeneity of asthma [26, 37]. These data 
include various birth cohorts which have tried to illuminate the influences, in particular 
early in life, that contribute to the development of a specific asthma endotype. 
Ongoing efforts to harmonize these date will allow joint analyses as well as 
comparisons between different cohorts, and thus contribute to more detailed 
definitions of wheeze phenotypes [82]. Through these and other efforts, certain 
endotypes have already been established, with the next paragraphs detailing a few of 
them that are of special interest for this work.  
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For example, a defunctional antiviral immunity of diminished interferon type 1 
production involving epithelial airway cells might be responsible for higher 
susceptibility to exacerbation in some asthma patients [73, 83]. Also, polymorphisms 
in IL-18, a cytokine potently inducing production of IgE as well as IFN-γ (leading to 
neutrophilia) and IL-13 (leading to airway remodelling), have been linked to certain 
asthma presentations [84]. 
Another proposed set of endotypes focuses on inflammation-resolving mechanisms. 
For example, the levels of anti-inflammatory IL-10 as well as the eicosanoid lipoxin 
A4 have been found to be lowered in severe asthma [85-87]. Eicosanoids are lipid 
mediators derived from arachidonic acid. The arachidonic acid metabolism in general  
is an interesting interface to study the balance of pro- and antiinflammatory stimuli. 
Additionally increasing this pathway’s relevancy for asthma is its relation to 
glucocorticoids whose anti-inflammatory capacities are mediated by the induction of 
lipocortin-1, which blocks phospholipase A2, inhibiting the synthesis of all eicosanoids 
[60]. 
The Th2-hypothesis mentioned above fits into the concept of endotypes as Th2-high 
endotype in allergic asthma with a specific Th2-gene expression. However, as 
already mentioned above, IgE alone does not appear to be a reliable biomarker, 
whereas the Th2-inducing IL-25 and basal eosinophilia are correlated with the 
response to asthma therapy in general, or steroids, respectively [54, 88, 89].  
 
On the plane of non-allergic asthma, Th17-cells driving neutrophilic inflammation 
might be responsible for the notorious steroid resistance in these patients, strongly 
linking this potential endotype to innate immunity [54, 90].  
Up to this point, innate immunity had been thought to play a minor role in chronic 
inflammatory processes like asthma as it was limited to acute inflammation [26]. 
Recently, inflammation mediated by innate immunity through DCs and macrophages 
has come into focus and its part has proved to be major. For example, the reduced 
ability of macrophages to find and remove defunct cells under oxidative stress results 
in activation of PRR through a spill of DAMPs, leading to auto-inflammatory 
processes in both innate and adaptive immunity [91]. These revelations could explain 
a considerable percentage of steroid insensitivity as well as why steroid sensitivity 
decreases when asthma severity increases, as the innate system per se is resistant 
to steroids [92]. 
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This brief overview of already proposed endotypes shows that investigating 
underlying mechanisms, especially in innate immunity, is a good starting point to gain 
more insight into asthma pathogenesis to define new, precise and consistent asthma 
endotypes, especially in non-Th2-related asthma [81].  
1.5 Immunological pathways in this work2 
In order to contribute to endotype definition and further understanding of asthma 
pathogenesis, this work will investigate pathways that, in previous studies mainly 
from our research group, have already shown to be differentially regulated in older 
children with asthma, or have been connected to asthma pathogenesis by others. 
Thus, the candidate genes chosen for this work contain receptors of the innate 
immune system as well as genes associated to calcium signalling, with the main 
question being whether their expression is already altered at birth.  
The following paragraphs will introduce and describe the candidate genes, mainly 
chosen based on previous results from our group reported by Boeck et al. showing 
differential gene expression in school age children in genes related to calcium 
signalling (namely, ATP2A3, CALM2, ITPR2, ORAI1, ORMDL3, S100A9, and STIM2 
among others) as well as genes associated with innate immunity (namely CD209, 
FPR2 and LY75 among others) [77]. 
1.5.1 Receptors related to calcium signalling 
The severity of asthma has long been coupled to a local increase in polycations such 
as calcium. Subsequently, perturbations in the mechanisms controlling the 
intracellular and extracellular concentration of calcium are of great interest in 
understanding the development of asthma. During (airway) inflammation or infection 
and the following activation of immune cells, the concentration of extracellular 
calcium ([Ca2+]e) is high as calcium serves as a danger signal [93]. It then leads to 
increased intracellular levels of calcium ([Ca2+]i), amplyfing inflammation by triggering 
pro-inflammatory signaling cascades. Also, a high [Ca2+]i primes airway smooth 
muscle cells to react to pathophysiological stimuli with a lower threshold, which in 
turn contributes to airway hyperreagibility and airway remodelling [94-97]. 
Physiologically, calcium is an important and versatile second messenger involved in 
signal transduction and apoptosis in many cells of the human body, also in the cells 
 
2 For a better overview of the candidate genes and their functions, see a graphical illustration (“gene 
map”) in the appendix (9.5). 
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of the innate immune system. It is stored in intracellular organelles such as the ER, 
which is responsible for keeping the cytoplasmatic levels at a constant 50-100 nM 
while the extracellular concentration of calcium is at approximately 1mM [96, 98]. Its 
function as a second messenger relies on subtle changes and oscillations in the 
cytoplasmic levels, evoked by many different mechanisms involving either cyclic 
adenosine monophosphate (cAMP) or, more important, inositoltriphosphate (IP3) as 
second messengers [99, 100]. 
 
Figure 4: Immunologically relevant pathways of calcium signalling in the cell. On the left, calcium release 
to the cytoplasm triggered by the TCR (T-cell-Receptor), on the right side of the membrane store-operated 
calcium entry (SOCE) through STIM1 (STIM2: not shown, but with equivalent function). In the lower left 
part, effects of intracellular calcium on transcription factors. InsP3: inositol triphosphate. InsP3-R: 
receptor for inositol triphosphate, equivalent to ITPR2. The calcium channel depicted is exemplary and 
could e.g. contain ORAI1. From [101]. 
IP3 is generated by the enzyme phospholipase C (PLC), which hydrolyses 
phosphatidylinositole-4,5-bisphosphonate (PIP2) to IP3 and diacylglycerole (DAG). 
PLC is activated upon stimulation of immunoreceptors like the TCR, the B-cell 
Receptor, Fc-receptor (responsible for phagocytosis and subsequent antigen 
presentation in macrophages) and mast cell receptor FceR (responsible for the 
release of mast cell mediators such as histamine) [98, 102].  
IP3, which can also be released via cAMP, then binds to its receptor, ITPR2,  a 
calcium channel located in the ER and thus, calcium is released from the ER to the 
cytoplasm [103, 104]. ITPR2 is predominantly expressed in mast cells and often 
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described as signal integrator, as it is most sensitive to ATP and IP3 but also ROS, 
and reacts to a low [Ca2+]i  with increased activity [105]. CAMKII and calmodulin 
terminate calcium influx via protein interaction, together with a negative intrinsic feed-
back through a high [Ca2+]i [106].  
 
Calmodulin 2 (CALM2) is a key protein for Ca2+ signal transduction as it serves as a 
primary receptor for elevated calcium levels and in turn activates CAMKII 
(calmodulin-dependent kinase II), a kinase selectively expressed in macrophages 
[98, 107]. It is activated by IP3, a mechanism regulated by STIM2 [108, 109] and 
ultimately signals to NFAT [110].  A proasthmatic effect of CAMKII through elevated 
generation of ROS and activation of the NLRP3 inflammasome as well as the NFκB 
pathway has recently been proposed especially for allergic asthma [111, 112].   
Store-operated calcium entry (SOCE) is a common mechanism also used by cells of 
the immune system to refill ER calcium stores and evoke Ca2+-signals, regulating a 
wide range of effector mechanisms including gene expression and cytokine release 
[113]. Stromal interaction molecules (STIM) 1 and 2 both detect depletion of the ER’s 
calcium stores and inflict changes on the intracellular [Ca2+]i. While they share the 
same function, they differ in sensitivity as STIM2 detects depletion with a higher 
sensitivity, i.e. earlier than STIM1. After depletion has been detected, STIM is 
translocated to the plasma membrane and interacts with ORAI1, the pore subunit of 
a store-operated calcium channel (SOCC) called CRAC [114-116]. CRAC is 
responsible for SOCE in T-Lymphocytes and mast cells, regulating activation or 
degranulation, respectively [102]. Additionally, STIM2 also influences non-store 
operated changes in calcium levels via CALM2 [109]. It is responsible for stabilizing 
the basal Ca2+ concentration via calcium oscillation and does so independently of 
STIM1, sometimes even antagonizing its effects [102, 117]. 
Once activated by binding of calcium to ORAI1, the CRAC channel opens and allows 
calcium entry through the plasma membrane [104]. In SOCE, ORAI1 is responsible 
for the amplitude of the calcium influx. Ultimately signalling to NFAT, it is very 
important for normal T-Cell-functioning [102, 118, 119]. Both ORAI1 and the CRAC 
channel are inactivated in a calcium-dependent manner through a cooperation of 
CALM2 with STIM1, effectively terminating SOCE [114, 120].  
The resting cytosolic calcium levels are then restored by ATP2A3, a sarco-
endoplasmatic reticulum Ca2+ - ATPase (SERCA) by pumping calcium from the 
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cytoplasm back to the ER [107, 121]. If ATP2A3 expression is diminished, a higher 
grade of airway remodeling, characteristic for asthma, has been observed [122].  
SERCAs such as ATP2A3 are controlled and inhibited by ORMDL3 [121]. In various 
studies, ORMDL3 and SNPs related to its expression have been directly associated 
with childhood asthma [123]. Also, ORMDL3 modifies T-lymphocyte activation by 
modulating SOCE after ligand binding to a TCR, as an increased expression of 
ORMDL3 leads to reduced NFAT signalling [118]. Apart from this influence on 
adaptive immunity, ORMDL3 is also involved in the mediation of cellular stress 
through e.g. unfolded protein response (UFR). An increase in intercellular calcium 
levels has been shown to disturb the ER’s correct folding of proteins, resulting in 
UFR [124]. 
Elevated levels of intracellular calcium, for example via the IP3- pathway, can also 
lead to the augmented presence of proteins called calgranulins in the outer 
membrane and to their release from phagocytes: S100A8 is such a calcium-binding 
protein mostly found in complex with S100A9 (then known as calprotectin) [125, 126]. 
They are abundantly expressed in inflammatory context, mainly in neutrophils and 
activated macrophages, where they promote inflammation by acting as DAMPs and 
through their chemotactic function for neutrophils [126-128]. Calcium binding results 
in signalling via MyD88, modulated by PGE2 and cAMP as well as IL-10, thus 
enhancing the effect of TLR signalling. This creates a positive feed-back loop as both 
S100A8 and S100A9 are induced by IL1β. S100A9 is also involved in airway 
remodelling via the induction of IL-17 [127-129]. Another property of S100A8 and 
S100A9 is their influence on the cell redox state mediated by ROS, which has for 
example been shown to mediate IgE-related mast cell signalling in allergic asthma as 
well as generally promoting inflammatory signalling through both the inflammasome 
and NFκB pathway [111, 112, 127, 129].  
Calprotectin is also involved in the metabolism of arachidonic acid, liberating 
arachidonic acid from the cell membrane through phospholipase A2, which is induced 
by pro-inflammatory cytokines like IL-6 and IL1β [128, 130]. Especially in mast cells 
and DCs, arachidonic acid is metabolized into leukotrienes (LT) and prostaglandines 
(PG), both promoting inflammation. Physiologically, there is a fine balance between 
the broncho-dilative PGs and strictly broncho-constrictive LTs, which is disrupted in 
asthma. Polymorphisms in the enzyme lipoxygenase which is responsible for the 
synthesis of leukotrienes have been related to asthma [131]. Leukotrienes are potent 
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mediators for smooth airway muscle contraction and pulmonary inflammation in 
asthma. More importantly, they are also said to modulate T-cell response in the 
direction of Th2-type inflammation [132].  
However, the arachidonic acid metabolites also include anti-inflammatory lipoxins, 
e.g. lipoxin A4, mediating a resolution of inflammation. Their concentrations have 
been found to be low in case of severe asthma [133]. Overall, a dysbalance of pro-
inflammatory leukotrienes and anti-inflammatory lipoxins seems to be a possible 
pathogenetic mechanism in severe asthma [134]. 
Lipoxins are recognized e.g. by the G-protein-coupled receptor FPR2, a mechanism 
through which FPR2 seems to protect from asthma exacerbations [133, 135]. FPR2 
is an example of how calcium signalling and innate immunity (in the form of pattern 
recognition receptors) interact. Similar points of interaction are of special interest in 
understanding the pathogenesis and interrelations of airway hyperreagibility and 
airway inflammation, as they seem to stem from imbalances in calcium signalling or 
innate immunity, respectively.  
1.5.2 Receptors related to innate immunity 
The main properties of FPR2 lie in innate immunity as it is expressed in neutrophils 
and monocytes. Its functions are similar to a PRR, recognizing a vast number of 
bacterial signalling peptides and formylpeptide, inducing the migration of DCs from 
the perivascular to the peribronchial tissues in allergic airway inflammation [136, 
137]. Upon ligand binding, FPR2 leads to ROS generation, an increase in the 
intracellular concentration of calcium via PLC activation and IP3, and to activation of 
the MAPK-pathway, influencing SOCE as well as transcription factors such as NFAT 
and NFκB [137].  
 
Another point of interaction, this time between innate and adaptive immune system, 
can be found in the NLRP3- inflammasome. It consists of three subunits: NLRP3, 
Caspase-1 and ASC, which serves as an adaptor for the previous two. Caspase-1 is 
the effector subunit which cleaves pro-IL1 and pro-IL-18, transscribed under the 
influence of NFB, into their mature forms. Its activation is triggered and regulated by 
various factors, cAMP and a high [Ca2+]i being very important [138-141].  
The inflammasome can also directly be influenced and activated by ROS. Some of 
the mechanisms influencing the cell redox state have already been mentioned above, 
another are RIG-I-like-receptors DHX58 and DDX58 and their shared adaptor protein 
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IPS1, all a part of the body’s viral defences through the recognition of viral structures 
like DNA [142, 143]. IPS1 is responsible for tight regulation of the RLRs’ effect upon 
ligand binding. Once activated, IPS1 signals to the inhibitors preventing NFκB from 
translocation to the nucleus and thus from actively influencing transcription, lifting this 
inhibition and allowing NFkB to translocate [142, 144]. Its other effector functions 
include the production of antiviral IFN1 that has been linked to a high susceptibility 
for asthma exacerbation (see chapter 1.4). 
The PRR LY75, which belongs to the CLR family, recognizes cell death material from 
virally infected or apoptotic cells and also acts as a mannose receptor. It is 
expressed in both immature and mature DCs, but changes its location from 
intracellular to surface when the DC is activated. Upon ligand binding, the antigen is 
taken up and enters the MHC-presentation pathways. In a steady state, DCs 
continuously process antigens for both the MHCI and the MHCII pathway, 
contributing to peripheral T-Cell tolerance, targeting CD4+, CD8+ and Treg cells [145, 
146]. LY75 expression is elevated in the lungs of patients suffering from allergic 
asthma, induced e.g. via the inflammasome product IL1β, potentially disrupting the 
balance between the induction of tolerance or immunity [147].  
Another CLR with a function similar to LY75 is CD209, which is upregulated via IL-13 
(an important cytokine in Th2-type immunity), to be found on immature DCs and 
macrophages, also in the lungs [58, 148]. Recognition of carbohydrates or Der-p, the 
main antigen of house dust mite, leads to endocytosis and antigen presentation via 
MHC II [149]. Additionally, the arachidonic acid cascade, which has been described 
above, is activated, especially in mast cells and DCs [150, 151]. 
Interestingly, both CD209 and LY75 seem to be dependent on calcium for ligand 
binding and downstream signalling, making them another point of interaction 
between calcium signalling and innate immunity [152]. 
CD209, like LY75, has tolerance-inducing capacities, e.g. by acetylation of NFB if 
an antigen is recognized without an additional inflammatory stimulus. In general, 
CLRs are said to modulate the immune answer after TLR activation [153, 154]. 
However, ligand binding leads to diminished expression of the receptor, a 
mechanism that, if constantly activated, has been proposed to increase the risk of 
life-long allergy and allergic asthma [58, 155]. 
 19 
1.6 Prediction of wheeze outcomes 
All of the receptors and proteins that have been chosen for further investigation in 
this work are part of keeping a fragile balance between tolerance and immunity as 
well as pro- and anti-inflammatory signalling. However, it is crucial for the immune 
system to learn how to keep this balance early in life, and a disruption facilitates the 
development of diseases like asthma.  
Appropriately, it is common for asthma to develop during early childhood, often even 
during the first few years of life. For the 30-40% of preschool children that experience 
wheezing, there are two possibilities: progression to childhood asthma or remission. 
It has been shown that in retrospect, 75% of children with persistent asthma had 
started to wheeze before age three, with their wheeze continuing first into school age 
and later into adulthood [13, 156]. In addition, studies have shown that the degree of 
severity tends to be firmly established early in life [157]. It is safe to say this group 
would largely benefit from early, consistent therapy.  
On the other hand, less than 50% of those patients who have experienced early 
childhood wheeze continue to do so [6, 158]. Also, according to current knowledge, it 
seems likely that patients who do remit do not develop another late-onset wheeze 
later in their lives [38]. Clearly separating these patients from those who will go on to 
develop childhood asthma is at least equally important as defining reliable asthma 
phenotypes: It would spare many children unnecessary treatments that inevitably 
have unwelcome side effects like for example steroids do, and in turn relieve the 
economic burden asthma represents for society. 
 
This overarching goal can be summarized as the improvement of the prediction of 
wheeze outcomes, with possible outcomes including remission as well as the 
different pheno- and endotypes of childhood asthma.  
Currently, there are several tools for diagnosing wheeze and asthma early in life, 
such as the ISAAC (International study of asthma and allergy in childhood) criteria 
[159] or the modified version of the asthma predictive index (mAPI) as an effort to 
improve the prediction value of the original API [160, 161]. Despite this attempt to 
improve the prediction value of the API, its usefulness in clinical practice remains the 
subject of controversial debate [162]. 
In the name of improving the prediction of wheeze outcomes as well as the clinical 
scoring systems needed for this prediction, many influences in the development of 
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asthma and the course of the disease have been discovered, both risk factors (such 
as virally induced wheezing episodes in early childhood [42] or a family history of 
atopy [163]) and protective factors such as farm exposure, whether prenatally or 
during childhood [164, 165].  
However, despite extensive research, currently very few diagnostic tools include the 
respective underlying immune mechanisms and the resulting endo- and phenotypes 
by for example adding biomarkers to the picture. This would certainly increase the 
predictive value of a score, as the important role of immunological pathways and their 
regulation in the pathogenesis of asthma is undisputed [28].  
Consequentially, this work seeks to identify possible new biomarkers in calcium and 
innate signalling, as including them in clinical scoring systems will lead to a more 
precise diagnosis and then to individualised phenotypes, enabling a personalized, 
effective therapy and thus relieving the burden of childhood asthma [2, 3, 166]. 
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2 Aim of the study 
Asthma starts to develop in early childhood, albeit two scenarios are possible for 
children with preschool wheeze: remission or progression to childhood asthma. 
Despite great efforts in research, the pathogenesis of asthma is still not well 
understood. Especially in-depth insights about the role of immune regulation in 
infancy are still missing, wasting the opportunity for early therapeutic interventions in 
children at risk for developing asthma. In order to optimize therapeutic strategies, it is 
crucial to identify children at risk for asthma development as early as possible. 
In addition, currently available therapeutic strategies are significantly lacking in two 
ways: They leave a considerable group of children under-treated with residual 
disease and inadequate symptom control. In contrast, another group of patients is 
over-treated for a wheeze that would eventually remit even without any intervention. 
Those groups would largely benefit from improved prediction of wheeze phenotypes 
as well as the classification of asthma into endotypes defined by their 
pathophysiology in order to administer individualized, effective therapy.  
Genome wide association studies (GWAS) have identified over 100 candidate genes 
and pathways linked to asthma development [26, 167]. The candidate genes chosen 
for this work had already raised interest through differential expression in other 
asthma cohorts investigated by our group. As it is becoming increasingly clear that 
prenatal events can already crucially shape the immune system, this study assessed 
immunological pathways at the earliest point possible, meaning directly at birth in 
cord blood mononuclear cells (CBMCs) [38, 166]. 
The aim of this study is to identify immune mechanisms underlying the pathogenesis 
of asthma that are already altered at birth in order to determine possible candidates 
for new biomarkers to predict and prevent the development of asthma in preschool 
children. Therefore, the following questions were assessed in this thesis: 
• To study whether genes of the calcium signalling pathway and selected innate 
receptors are expressed in cord blood immune regulation of neonates. 
• To investigate if the expression of the chosen genes at birth differs between 
children with subsequent different wheeze patterns and healthy controls.  
• To specifically study whether a pattern in gene expression variation can be 
found between children with multitrigger wheeze and other wheeze patterns 
as well as healthy controls.  
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• To specifically study whether a pattern in gene expression variation can be 
found between children with virally induced wheeze and other wheeze 
patterns as well as healthy controls.  
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3 Materials and methods 
3.1 Materials 
3.1.1 Reagents and chemicals  
0.5M EDTA (pH 8.0) Sigma-Aldrich, St.Louis, USA 
100bp DNA ladder (500μg/ml) New England BioLabs, Ipswich, USA 
Agarose LE Biozym Scientific, Oldendorf, Germany 
Boric Acid Sigma-Aldrich, St.Louis, USA 
Bromphenol blue Roth, Karlsruhe, Germany 
Ethidiumbromide (10mg/ml) Biorad, Hercules, USA 
Glycerol Sigma-Aldrich, St.Louis, USA 
H2O bidest H.Kerndl GmbH, Weißenfeld, Germany 
Primers Life technologies, Invitrogen, Carlsbad, USA 
Trizma Base Sigma-Aldrich, St.Louis, USA 
Xylene cyanol Merck, Darmstadt, Germany 
 
3.1.2 Solutions and buffers 
5X TBE buffer  
 
54g trizma base  
27.5g boric acid  
20ml 0.5M EDTA (pH 8.0)  
1l H2O bidest.  
 
DNA ladder  
 
10μl 100bp DNA ladder  
80μl 0.5x TBE-Buffer  
10μl loading dye diluted solution  
 
Ethidiumbromide [500μg/ml]  
 
Loading dye stock solution  
 
100μl ethidiumbromide  
1.9 ml H20  
0.25g bromphenol blue 
0.25g xylene cyanol 
30% glycerol 
70ml dH2O 
 
Loading dye diluted solution  
 
5ml loading dye stock solution  
13.5ml glycerol  
31.5ml dH2O  
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3.1.3 Reagent kits 
QuantiTect Reverse Transcription Kit Qiagen, Hilden, Germany  
 
Sso Advanced Universal SYBR Green 
Supermix 
Biorad, Hercules, USA  
 
 
3.1.4 Consumables 
96-Well White Shell PCR Plates BD Biosciences, Heidelberg, Germany 
Biosphere® filter tips 0.1-20μl  Sarstedt, Heidelberg, Germany 
Biosphere® filter tips 100-1000μl Sarstedt, Heidelberg, Germany 
Biosphere® filter tips 2-100μl Sarstedt, Heidelberg, Germany 
Microseal “B” Seal Biorad, Hercules, USA 
 
3.1.5 Laboratory equipment 
CFX 96 Touch ™ Real-Time PCR 
Detection System 
Biorad, Hercules, USA 
Electrophoresis power supply VWR International, Radnor, USA 
Gel iX Imager Intas Science Images Instruments, 
Göttingen, Germany 
Nanodrop 2000 Thermo Scientific, Waltham, USA 
Owl D3-14 wide gel electrophoresis 
system 
Thermo Scientific, Waltham, USA 
PeqStar Thermocycler Peqlab, Erlangen, Germany 
Perfect Spin P Peqlab, Erlangen, Germany 
Research plus pipette 10-100μl Eppendorf, Hamburg, Germany 
Research plus pipette 0.5-10μl Eppendorf, Hamburg, Germany 
Research plus pipette 0.1-2.5μl Eppendorf, Hamburg, Germany 
Research plus pipette 2-20μl Eppendorf, Hamburg, Germany 
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3.1.6 Software 
Biorad CFX Manager 2.1 Biorad, Hercules, USA 
Endnote X9 ISI ResearchSoft, Berkeley, USA 
Ensembl genome browser http://www.ensembl.org 
National Center for Biotechnology 
Information 
http://ncbi.nlm.nih.gov 
Vector NTI Advance 11.5 Invitrogen, Carlsbad, USA 
SPSS Statistics 23.0 
R 
IBM, Armonk, New York, USA 
General Public License under the 
Free Software Foundation 
 
3.1.7 Primer sequences 
The primer sequences used for this work can be found in the appendix (9.4). 
3.2 Study population3 
3.2.1 PAULINA 
As a part of the birth cohort PAULINA (Pediatric Alliance For Unselected Longitudinal 
Investigation of Neonates for Allergy), umbilical cord blood was obtained from healthy 
neonates (n=118), although due to sample availability or non-participation in the 
follow up, the number available for single analyses varied, born in the Munich 
metropolitan area, Germany [168]. Midwives and delivery room nurses recruited 
subjects from October 2004 to September 2007 during the last trimester of 
pregnancy at the university’s women’s hospital (Frauenklinik Maistraße, Munich). 
Inclusion criteria comprised healthy neonates (assessed via APGAR score and 
clinical evaluation) and mothers with uncomplicated pregnancies. Exclusion criteria 
included preterm deliveries, multiple gestations, maternal infections and/or use of 
antibiotics during the last trimester, perinatal infections and chronic maternal 
diseases. Questionnaires were used to assess parental health and socioeconomic 
status as possible covariates.  
The birth cohort comprises peripheral blood samples (1ml EDTA and 4,9ml serum) 
from atopic mothers (n=48) and non-atopic mothers (n=70) as well as cord blood 
samples from their children (see below). Atopy was defined as a doctor’s diagnosis of 
 
3 All questionnaires mentioned in the following paragraphs can be found in the appendix (9.6).  
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asthma and/or eczema and/or hay fever. Additionally, maternal total and specific IgE 
were measured via radio-allergo-sorbent test (RAST), with a positive specific IgE 
defined as ≥0.35 IU/mL to one or more common allergens from a panel of 20 
allergens (Mediwiss Analytic, Moers, Germany). Approval was obtained from the 
human ethics committee of the Bavarian Ethical Board, LMU Munich, Germany. For 
detailed study information, see [168].  
 
3.2.2 PAULCHEN 
In the PAULCHEN Study (Prospective Cord Blood Study in Rural Southern 
Germany), 82 mothers were approached before delivery. The cohort included 
farming (n=22) and non-farming (n=60) mothers. Subjects were recruited from 
September 2005 until December 2008 in the obstetric clinic of Bad Tölz, Germany 
[68]. Farming was defined as the mother living or regularly working on a farm in the 
last five years and/or during pregnancy. Non-farming mothers lived in the same rural 
area, without having direct contact to a farm environment. Inclusion and exclusion 
criteria as well as potential covariates were equivalent to the previously described 
PAULINA-Study. Approval was obtained from the human ethics committee of the 
Bavarian Ethical Board, LMU Munich, Germany. For detailed study information, see 
[68]. 
3.2.3 Outcome at age three and age six 
As the recruited children reached age 3 and then age 6, follow-ups on the study 
populations were performed. All data were collected by detailed questionnaires filled 
in by the parents, including epidemiologic parameters (e.g. socio-economic status 
and parental smoking). The children’s possible outcomes included atopic dermatitis, 
food allergy, wheeze (clinical symptoms and doctor’s diagnosis) and sensitization to 
allergens, measured by specific IgE in a part of the study population. A positive 
allergen test was defined by at least one positive specific IgE to one of twenty 
common inhaled or food allergens. The 6-year follow-up questionnaire additionally 
included outcomes of allergic comorbidities such as rhinoconjuctivitis. 
3.3 Laboratory methods 
The main focus of this work was to investigate gene expression via qRT-PCR in RNA 
from CBMCs, and to compare gene expression levels between different subsets of 
wheeze in the follow-ups of the birth cohorts described, which were recruited from 
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2004 onwards. Thus, naturally some of the laboratory methods were not conducted 
by the author herself but by other members of the laboratory. 
For the sake of completeness, all laboratory methods involved in this study will be 
described in the following paragraphs. However, every step that was not conducted 
by the author herself will be marked with an asterix (*). 
3.3.1 Study inclusion procedure and criteria 
3.3.1.1 Collection of cord blood (*) 
Parents gave informed written consent about participation in the study. In case of 
uncomplicated, on-term delivery, cord blood was drawn from the umbilical vein of 
healthy neonates. A volume of 30 ml, separated in 10 ml tubes coated with liquemin 
as anticoagulant was obtained in most cases. 
3.3.1.2 Isolation and culture of cord blood mononuclear cells (CBMCs) (*) 
Cord blood samples were processed within a maximum of 24 hours after withdrawal. 
CBMCs were isolated by density-gradient centrifugation with Ficoll-Hypaque 
(Amersham Bioscience, Uppsala, Sweden) after dilution in phosphate buffer saline 
(PBS, Gibco, Karlsruhe, Germany). Cells were centrifuged for 30 min at 20°C with 
1400 rpm, then resuspended in RPMI 1640 (Gibco, Carlsbad, USA) until a dilution to 
5x106 cells/ml in 10% human serum (Sigma Aldrich, Steinheim, Germany) was 
reached. CBMCs were then cultured unstimulated or stimulated with lipid A (LpA, 
0.1μg/ml) or phytohemagglutinin (PHA, 5μg/ml) for 72h.  
Lipid A is the biologically active component of LPS, an endotoxin of gram-negative 
bacteria, stimulating innate immune cells. 
Phytohemagglutinin is a potent mitogen, stimulating mainly T-cells. 
3.3.2 RNA extraction (*) 
One millilitre TRIzol (Invitrogen, Carlsbad, Germany) was added to the harvested and 
centrifuged CBMCs. Samples were then frozen at -80°C. After thawing, 0.2ml 
chloroform was added and the samples were centrifuged at 4°C and 1200 rpm for 15 
minutes. The supernatants of the RNA precipitation were discarded and 0,5 ml 100% 
Isopropanol as well as 1μl Glycogen were added. After another centrifugation 75% 
Ethanol was added and samples were centrifuged again for 5min. Samples were 
then dried for 10-30min at 42°C and, after resuspending in RNAse-free water, 
incubated at +60°C. RNA was stored at -80°C. 
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3.3.3 cDNA extraction4 
Concentration of the extracted RNA was measured via photometry (nanodrop 2000, 
Thermo Scientific, Waltham, USA). 1μg RNA was transferred to 20μl cDNA with a 
Quantitect-kit (Quiagen, Hilden, Germany), including a wipe out of genomic DNA. 
cDNA was stored at -20°C. 
3.3.3.1 Primer design 
DNA primers used for PCR are chemically synthesized oligonucleotides of about 
20bp. They are needed as starting point for the DNA-synthesizing enzyme, 
polymerase. Primers for the genes explored in this work were designed with “Vector 
NTI Advanced10” (Invitrogen, Carlsbad, USA) and were then ordered at Invitrogen. 
Sequences were drawn from the genome database “Ensembl”, a joint project of the 
European Bioinformatics Institute (EBI), the European Molecular Biology Laboratory 
(EMBL) and the Wellcome Trust Sanger Institute (WTSI).  
The following rules were applied to find pairs of forward (fw) and reverse (rv) primers: 
1. Primer length should be between 18 and 27 base pairs. 
2. The resulting PCR product should be about 200 base pairs long. 
3. The 3’ end of each primer should start with guanine (G) or cytosine (C). 
4. The content of guanine (G), cytosine (C) should be between 40% and 60%.  
5. The melting temperature of each primer should be between 54°C and 65°C, 
with the difference in temperature between the forward and the reverse primer 
being no bigger than 0.5°C. 
6. Primers have to be behind the start codon (ATG), as transcription to mRNA 
starts only after this sequence. 
7. The energy by which the primers form dimers or hairpins should be no more 
than +/- 2kcal/mol, because otherwise the primers will not anneal themselves 
to the cDNA in a sufficiently specific way.  
8. The distance between the forward and the reverse primer should be as wide 
as possible, e.g. covering multiple exons, to limit the possibility of unspecific 
amplification.  
The delivered primers were first diluted with DEPC-water to a stock of 1mM. Then, 
with an intermediate dilution to 0.1mM, the final dilution of 1μM was used for PCR, 
containing both forward and reverse primer. The final dilution was stored at +4°C.  
 
4 For this, the author was partly supported by the laboratory’s technician. 
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All primers were tested in a two-step scheme. First, the primer was tested with cDNA 
from test samples, with a focus on whether any amplification was detected at all. 
Also, the melting curve was analysed. 
In the second step, the primer was tested on its specificity for cDNA by performing a 
test-qRTPCR with DNA and RNA. If no amplification occurred, the primer was 
considered as usable for qRT-PCR.  
In case amplification occurred when testing with DNA, an exception was made if the 
melting curves of DNA product and cDNA product were clearly distinguishable 
through different melting temperatures. Additionally, contamination of the isolated 
RNA and thus the cDNA with DNA was considered as highly unlikely. 
 
3.3.4 Polymerase chain reaction (PCR) 
3.3.4.1 Principle of the Polymerase chain reaction  
 
PCR (short for polymerase chain reaction) is a method imitating physiological 
processes used to specifically amplify even small fragments of DNA.  
Basically, the double helix formation of the DNA is heat denaturized. The two 
complimentary single strand DNA molecules are annealed after the specific primers 
bound to their complimentary sequence. Then, a heat-stable polymerase 
resynthesizes a complementary strand to each of those single strands, effectively 
duplicating the original fragment.  
 
A typical PCR thus consists of three steps being repeated in multiple cycles: 
 
1. Denaturation: the already existing double strand(s) are melted into single 
strands at 95°C before each cycle. 
2. Annealing: at 62.5°C, hybridization of primers at the 5’-3’-ends of the single 
strands that are to be amplified within 30 seconds. Choosing the right 
temperature for this step is crucial to avoid non-specific PCR products like e.g. 
primer dimers. All temperatures mentioned in this paragraph are specific for 
this work.  
3. Elongation: at 72°C, the aforementioned heat-stable taq-polymerase starts to 
elongate the primers. The desoxyribonucleotid-triphosphates needed for this 
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step are part of the mastermix, added in abundance. Elongation stops once 
the polymerase reaches the end of the single strand, or the temperature raises 
once cycle restarts with denaturation. 
In theory, the DNA is amplified exponentially, as shown by this equation: 
Nn = N0 x 2n 
 
Nn : amount of cDNA after the nth  cycle 
N0 : original amount of cDNA at the start of the PCR  
n : number of cycles 
 
However, this equation assumes that the taq-polymerase is working with 100% 
efficiency. As this efficiency is not reached in practice, the analysis of PCR data 
includes an efficiency correction. 
3.3.4.2 Quantitative real-time PCR (qRT-PCR) 
In this work, gene expression in stimulated and unstimulated CBMCs was studied at 
mRNA level. To allow the assessment of mRNA, it was transcribed to cDNA. The 
cDNA was then used for qRT-PCR.  
In addition to traditional PCR, quantitative real-time PCR permits conclusions to be 
drawn about the quantity of the original product that was to be amplified. 
Quantification is obtained by fluorescence measurements, as the fluorescence 
increases proportionally with the amount of PCR product.  
In this case, Sso Advanced Universal SYBR Green Supermix (Bio-Rad, Hercules, 
USA) was used as fluorescent dye for qRT-PCR. It intercalates in (c)DNA and then 
starts to fluoresce.  
The cycle of threshold (Ct) describes the cycle during which a fluorescent signal 
above a background signal, thus coming from the PCR product, is detected. 
Consequentially, the Ct value is linked to the original amount of cDNA: The lower the 
Ct value, the higher the initial concentration cDNA. In regard to cDNA, or respectively 
mRNA, a lower Ct value equals higher gene expression. For objective analysis, all Ct 
values are referred to the Ct value of the housekeeping gene with stable and 
ubiquitous expression. In this work, 18S was used as housekeeping gene like. 
However, SYBR Green detects all kinds of double stranded cDNA, also primer 
dimers or unspecific PCR products, thus necessitating a melting curve analysis.  
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3.3.4.3 Preparatory calculations 
For PCR, a mastermix, a cDNA-Mix and an NTC-Mix (for the non-template controls) 
were prepared.  
In all calculations, n indicates the number of wells. 
• For the mastermix: (n + 2 pipetting error) x 5μl SYBR Green, equivalent to 5 μl 
mastermix per well 
• For the cDNA-Mix per condition: (n + 1 pipetting error) x (0.12 μl cDNA + 1.68 
μl DEPC), equivalent to 1.8μl per well 
• For the NTC-Mix: (n + 1 pipetting error) x (1.8 μl DEPC + 5 μl SYBR Green), 
equivalent to 6.8μl per well 
In addition, 3.2μl of final primer dilution were added to each well, resulting in a total 
volume of 10μl per well. 
3.3.4.4 Pipetting scheme 
As can be seen in this scheme, a 96-well-plate (Bio-Rad, Hercules, USA) was used.  
 
Table 1 : Pipetting scheme used for this work. Colums 1-12 each represent a gene of interest while rows 
indicate a stimulating condition (A-F), the housekeeping gene (G) or NTCs (H), respectively. 
 
For pipetting, all reagents were stored and processed on ice. 18S was used as 
housekeeping gene and thus applied next to the 12 genes of interest investigated in 
this study.  
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
 
S100A8 
M 
S100A9 
M 
ORMDL3 
M 
IPS1 
M 
ATP2A3 
M 
ITPR2 
M 
ORAI1 
M 
STIM2 
M 
LY75 
M 
CD209 
M 
FPR2 
M 
CALM2 
M 
B S100A8 
M 
S100A9 
M 
ORMDL3 
M 
IPS1 
M 
ATP2A3 
M 
ITPR2 
M 
ORAI1 
M 
STIM2 
M 
LY75 
M 
CD209 
M 
FPR2 
M 
CALM2 
M 
C S100A8 
PHA 
S100A9 
PHA 
ORMDL3 
PHA 
IPS1 
PHA 
ATP2A3 
PHA 
ITPR2 
PHA 
ORAI1 
PHA 
STIM2 
PHA 
LY75 
PHA 
CD209 
PHA 
FPR2 
PHA 
CALM2 
PHA 
D S100A8 
PHA 
S100A9 
PHA 
ORMDL3 
PHA 
IPS1 
PHA 
ATP2A3 
PHA 
ITPR2 
PHA 
ORAI1 
PHA 
STIM2 
PHA 
LY75 
PHA 
CD209 
PHA 
FPR2 
PHA 
CALM2 
PHA 
E 
 
S100A8 
LpA 
S100A9 
LpA 
ORMDL3 
LpA 
IPS1 
LpA 
ATP2A3 
LpA 
ITPR2 
LpA 
ORAI1 
LpA 
STIM2 
LpA 
LY75 
LpA 
CD209 
LpA 
FPR2 
LpA 
CALM2 
LpA 
F S100A8 
LpA 
S100A9 
LpA 
ORMDL3 
LpA 
IPS1 
LpA 
ATP2A3 
LpA 
ITPR2 
LpA 
ORAI1 
LpA 
STIM2 
LpA 
LY75 
LpA 
CD209 
LpA 
FPR2 
LpA 
CALM2 
LpA 
G 18S 
M 
18S 
M 
18S 
PHA 
18S 
PHA 
18S 
LpA 
18S 
LpA 
     18S 
NTC 
H S100A8 
NTC 
S100A9 
NTC 
ORMDL3 
NTC 
IPS1 
NTC 
ATP2A3 
NTC 
ITPR2 
NTC 
ORAI1 
NTC 
STIM2 
NTC 
LY75 
NTC 
CD209 
NTC 
FPR2 
NTC 
CALM2 
NTC 
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All experiments were run in duplicates. The non-template controls and dissociation 
curves were used to rule out unspecific amplifications and primer-dimers. 
After finishing the pipetting process, the plate was sealed with optical foil (Bio-Rad, 
Hercules, USA) and then centrifuged at 2500 rpm (rotations per minute) for 15 
seconds to eliminate any bubbles. 
Afterwards, the plate was placed in the iCycler (Bio-Rad, Hercules, USA) and the 
protocol was started. 
3.3.4.5 Protocol iCycler 
 
Cycle 1: (1x)  
  
95.0°C  
 
2 minutes  
(= Initial denaturation)  
 
    
Cycle 2: (40x)  
 
  
Step 1: 
  
Step 2:  
 
95.0°C  
 
62.5°C  
 
20 seconds  
(= Denaturation)  
30 seconds 
(=Annealing + Elongation)  
 
Cycle 3: (1x)    
72.0°C  
 
2 Minuten  
(=Elongation)  
 
Cycle 4: (1x)   95.0°C  30 seconds  
Cycle 5: (1x)   55.0°C  30 seconds  
Cycle 6: (80x)   55.0°C  5 seconds  
 Cycle 7: (1x)  20.0 °C HOLD 
 
3.3.4.6 Gel electrophoresis 
Electrophoresis describes the migration of molecules in an electric field depending on 
their charge and size. Gel electrophoresis is a method used for additional PCR 
quality control (for further explanation, see below). 
In this work, three percent agarose gel plates were used. For this, 6g agarose 
(Biozym Scientific, Oldendorf, Germany) solved in 200ml of 0.5% buffer (900ml aqua 
bidest + 100 ml 5xTBE) were heated up to boil until the solution was clear. After 
cooling down to 80°C, 70 μl ethidium bromide (Biorad, Hercules, USA), which 
intercalates with DNA and visualizes it in UV light, were added and the gel (14x23cm) 
was cast. The gel chamber (30x27x11cm, buffer volume 800ml, Thermo Scientific, 
Waltham, USA) was prepared with several combs, forming pockets in the gel after 
their removal when the gel was completely cooled down. 
For performing the gel electrophoresis, 2μl loading dye was added to all PCR 
products as well as the NTCs.  
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PCR products, NTCs and the “ladder”, a solution containing DNA fragments of known 
sizes, used to quantify the size of the PCR products, were pipetted into the gel’s 
pockets. 
The gel chamber was then connected to 120V voltage and 400mA current for 40 
minutes. Afterwards, the gel was evaluated and then photographed under UV light.  
3.3.4.7 qRT-PCR analysis 
After completion of the iCycler protocol, data were analysed with the associated 
program (Bio-Rad, Hercules, USA). 
 
 
 
 
 
 
 
 
 
 
The x-axis shows the number of PCR cycles, while the y-axis shows the intensity of 
the fluorescence signal. The green line (y-axis value 50) is the visualization of the Ct, 
in this case set by the iCycler and not manually. It should lie at the beginning of the 
exponential phase of amplification. The Ct value is what later is used for statistical 
analysis.  
3.3.4.8 Quality control 
3.3.4.8.1 Melting curve analysis 
Melting curve analysis is a method to check for specificity in PCR. The melting curve 
is created by the iCycler by constantly measuring the fluorescent signal while raising 
the temperature in steps of 0.5°C. The PCR product denaturates at a specific 
temperature, represented ideally in a narrow, high peak in the melting curve. 
Unspecific amplification, such as primer dimers, can be recognized by low, broad 
melting curves.  
Figure 5: Exemplary amplification of cDNA. The both 
lines each represent one of the duplicates. 
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The specifity of all data generated by the iCycler was primarily assessed through 
melting curve analysis. In case of unspecific amplification (see Fig.7), the duplicate in 
question was repeated in order to obtain specific results. 
 
 
Figure 7: Exemplary melting curves. In blue: unspecific amplification. In dark grey: height difference in 
two duplicates. In orange: two duplicates, none of which were detectable. 
If the height of the melting curve of two duplicates showed differences equivalent to a 
difference in Ct values greater than 0.7, they were also repeated (see fig.7). This was 
done in order to minimize the influence of technical mistakes and other disturbances. 
If a technical error was already noted during the pipetting process, this duplicate was 
excluded and only the other duplicate was used.  
If both duplicates failed to reach a detectable Ct after 40 cycles of amplification but a 
technical error could be excluded they were both marked as “non-detects” and set to 
an artificial Ct value of 40, which represents the last possibly measured cycle, so they 
were not lost to analysis. 
Figure 6: Exemplary melting curve with typical 
characteristics of specific amplification. 
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3.3.4.8.2 Gel electrophoresis 
PCR products were separated via gel electrophoresis for additional quality control. 
Specificity was evaluated by comparing the expected size of the amplification product 
(around 200bp) with the scale provided by the ladder. 
Also, the electrophoresis was another mean to control the duplicates’ consistency.   
If the PCR product consisted only of the specific sequence demarcated by the primer 
used, a single, sharply outlined band showed in the electrophoresis. 
3.3.5 Statistical analyses5 
Data analysis was performed with SPSS Statistics and R.  
Epidemiological parameters were assessed for differences in phenotypes for the 
study population and screened for possible confounders. Continuous parameters 
were analysed with the Wilcoxon test, categorical variables with the Chi-square test. 
The effect of stimulation with either PHA or LpA in comparison with unstimulated 
cells was assessed using the t-test after calculating the fold change after stimulation. 
Fold change = (log2 -   Ct) 
For the analysis of the PCR data, the ΔCt was calculated by using 18S as 
housekeeping gene, as it is ubiquitously and stably expressed. 
ΔCt (gene of interest) = Ct (gene of interest) - Ct (18S) 
As all experiments were run in duplicates, mean ΔCt values were calculated for all 
duplicates in the next step.  
ΔCt (mean) = ½ (ΔCt (duplicate A) + ΔCt (duplicate B))  
Differences in the expression rates between two subgroups were assessed with the 
Wilcoxon two sample rank sum test.  
Statistical significance was defined as p ≤ 0,05. P values with p ≤ 0,1 were defined as 
trends.  
As no confounders were found in our analysis, a stratified analysis of data was not 
necessary. 
 
5 For the statistical analysis, the author was supported by the laboratory’s statistician. 
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4 Results 
4.1 Study population 
4.1.1 Characteristics 
Epidemiological and clinical data about the children included in PAULINA or 
PAULCHEN, respectively, were collected from detailed questionnaires filled in by the 
parents at birth as well as at age three and six6. For more detailed information about 
the design of each study, see chapter 3.2. As the inclusion and exclusion criteria as 
well as the parts of the questionnaires relevant for this work were equivalent in 
PAULCHEN and PAULINA, they will no longer be distinguished in the following. 
4.1.2 Assessment of outcome at age six 
Based on the information from the questionnaires, patients were assigned to one of 
four previously defined subgroups – multitrigger wheeze, persistent viral wheeze, 
transient early viral wheeze and healthy controls. Those subgroups, each comprising 
a specific clinical outcome, were later compared to each other in order to find 
differences in gene expression in CBMCs at birth. In order to avoid the creation of too 
many subgroups, categorization focused on a small number of questions. 
The definitions applied to the three-year follow-up were equivalent to those applied to 
the six-year follow-up. 
   
Figure 8 : Schematic representation of the four subgroups used in this work. 
 
6 All questionnaires can be found in the appendix (chapter 9.6). 
Virally triggered
wheeze at 3-year 
follow-up and 6-
year follow-up
Wheeze only at 
3-year follow-up
but healthy at 6-
year follow-up
No wheeze, 
neither at 3-year 
follow-up nor at 
6-year follow-up
Wheeze with
multiple triggers
at 3-year follow-
up and 6-year 
follow-up
Multitrigger 
wheeze
(n=14)
Transient 
early viral 
wheeze
(n=14)
Healthy
controls
(n=14)
Persistent 
viral 
wheeze
(n=14)
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Healthy controls (HC) were defined as children who did not have wheeze in both the 
three-year and the six-year follow up. Children whose parents answered “yes” to the 
question “has your child ever had wheeze” were classified as “any wheeze”. 
Additionally, a (repeated) doctor’s diagnosis of obstructive bronchitis was also 
classified as the child having shown wheeze. This large group was then further 
divided.  
“Transient early viral wheeze” (TEV) was defined to include children who classified 
as “viral wheeze” in the three-year follow up, with wheezing only during viral infection 
(see below), but whose parents in the six-year follow-up, answered “no” to the 
question “did your child ever show wheeze in the last three years”.  
Children whose parents answered “yes” to the question “has your child shown 
wheeze in the last three years” in both three- and six-year follow-up could either 
classify as “persistent viral wheeze” or “multiple trigger wheeze”. 
Of those children, “persistent viral wheeze” (PV) contains all whose parents indicated 
that they only wheezed when they had an infection of the airways (i.e. wheezy 
bronchitis) but not outside of these episodes. This had to be stated in both the three-
year and the six-year follow-up. 
For “multiple trigger wheeze” (short: multitrigger or MT), parents had to either report 
that their child’s wheeze was also present without infection and triggered either by 
effort, contact to animals, house dust, grass, or others, or a doctor’s diagnosis of 
obstructive bronchitis. In case of an additional doctor’s diagnosis of an allergic 
comorbidity, like rhinoconjuctivitis, or an allergic sensitization (either parent-reported, 
diagnosed by a doctor, or a positive specific IgE if it was available) was indicated in 
the questionnaire, the child in question was also classified as MT. 
In contrast to PV, this could be stated in either the three- or the six-year follow-up, or 
both. Children who were pulmonally healthy in the three-year follow up but filed as 
MT in the six-year follow up were summarized as “late-onset-multitrigger wheeze” 
(LOM). Viral wheeze in the three-year follow-up, which changed to multitrigger 
wheeze in the six-year follow-up, was classified as “viral to multitrigger wheeze” 
(VM). In contrast, the group who showed multitrigger wheeze in both follow-ups was 
called “persistent multitrigger wheeze” (PM). For reasons of case numbers, these 
three individual subgroups were summarized as MT for sample selection and for a 
part of the analysis. 
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For more detailed information on the questions asked, see the complete 
questionnaires in the appendix as well as the summary table below. 
Phenotype Question 1: 
“Has your child 
ever had 
wheezing?” 
Question 2: 
“Has your child 
wheezed in the 
past 3 years?” 
Additional questions (for more exact 
definition of phenotype) 
Pulmonary  
healthy (H) 
No No ‘Has your child been prescribed 
medication for wheezing or shortness of 
breath in the last 3 years?’: no 
‘Has your child been diagnosed with 
obstructive or convulsive bronchitis or 
asthmatic bronchitis?’: no 
Multitrigger 
wheeze (MT) 
Yes Yes/no ‘What triggers the wheezing?’: at least 
two different triggers 
‘How often does your child wheeze when 
they are not having an acute infection?’: 
at least once a month 
Doctor’s diagnosis of obstructive 
bronchitis  
Yes Yes Positive allergy test  
Positive for rhinoconjunctivitis 
Positive for atopic dermatitis 
Viral wheeze 
(V) 
Yes Yes/no  ‘Is your child completely symptom-free 
between the wheezing episodes?’: yes 
‘How often does your child wheeze when 
they’re not having an acute infection?’: 
never 
Table 2 : Summary table of questions especially relevant for phenotype definition. 
 
4.1.3 Sample selection 
Sample selection was based on a case-control design matched for potential 
confounders. As the limiting group was, consistent with known prevalence, 
multitrigger wheeze with n=14, an equal number was selected from the other, larger 
groups. Those were selected aiming for high homogeneity regarding the variables 
shown in Table 3. Ultimately, a number of n=56 were selected for the analyses of this 
work. As possible confounders were eliminated through the described matching 
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process, there was no need for stratified analyses. The allocation of the samples 
chosen is shown in Figure 9.  
 
Figure 9: Schematic representations for the subgrouping of samples used in this work. N=14 for the MT 
group result from summarizing late onset multitrigger wheeze, viral to multitrigger wheeze and persistent 
multitrigger wheeze. 
 
The epidemiological and socioeconomic characteristics of this smaller cohort are 
shown in the following table.  
Pulmonary
healthy (H)
22
Viral wheeze
(V)
30
Multitrigger 
wheeze (MT)
4
Age 3
Age 6 H
14
V
0
MT
8
H
14
V
14
MT
2
H
0
V
0
MT
4
Healthy
controls
14
Persistent 
multitrigger
wheeze
4
Age 3+6
Early viral 
wheeze
14
Persistent 
viral 
wheeze
14
Viral to
multitrigger
wheeze
2
Late Onset
multitrigger
wheeze
8
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 MT (n=14) HC  (n=14) PV (n=14) TEV (n=14)  
Female sex  43% (6) 43% (6) 43% (6) 29% (4) p=0.83 * 
Gestational age (weeks) 40.1 39.7 40.1 39.9 p0.1 # 
Birth weight (g) 3693 3411 3660 3628 p0.1 # 
Birth length (cm) 52.2 51.5 52.6 52.3 p0.15 # 
Family history      
Mother asthmatic 14% (2) 7% (1) 43% (6) 21% (3) p=0.12 * 
Mother atopic 
 
57% (8) 64% (9) 71% (10) 64% (9) p=0.89 * 
Father asthmatic 7% (1) 21% (3) 0% (0) 7% (1) p=0.24 * 
Father atopic 57% (8) 50% (7) 21% (3) 57% (8) p=0.18 * 
Maternal smoking     p=0.67 * 
No 86% (12) 86% (12) 64% (9) 86% (12)  
Yes 0% (0) 0% (0) 7% (1) 7% (1)  
Until pregnancy 7% (1) 14% (2) 14% (2) 0% (0)  
Quit before pregnancy 7% (1) 0% (0) 14% (2) 7% (1)  
Maternal education     p=0.05 * 
Basic school certificate  14% (2) 0% (0) 14% (2) 0% (0)  
Secondary school certificate  29% (4) 7% (1) 14% (2) 0% (0)  
High school degree 14% (2) 43% (6) 7% (1) 14% (2)  
University 43% (6) 50% (7) 64% (9) 86% (12)  
Table 3: Description of the analysed subgroup of the birth cohort. Mother/father atopic: doctor’s 
diagnosis of atopy or atopic disease (hay fever, atopic dermatitis). Mother/father asthmatic: doctor’s 
diagnosis of asthma. Maternal education: highest degree or certificate reached by the mother. MT 
multitrigger wheeze, HC healthy control, PV persistent viral wheeze, TEV transient viral wheeze. 
Percentages and absolute number of subjects (indicated in brackets) shown. Test statistic based on the 
Chi-Square-Test for categorical variables (*) and ANOVA for continuous variables (#). 
 
4.2 Gene expression7 
4.2.1 Description 
In general, most genes from most children were detectable, i.e. their Ct was below 
the detection limit of 40 cycles8. However, several non-detectables, with a Ct above 
the detection limit also occurred. This is to be expected in CBMCs, as gene 
expression is generally lower than in other cell populations like e.g. PBMCs 
(peripheral blood mononuclear cells), and especially in unstimulated CBMCs. In case 
both duplicates showed a Ct >40 and technical issues as possible cause were ruled 
 
7 For a better overview, see the gene map in the appendix. 
8 In qRT-PCR, a low Ct value indicated high gene expression, and vice versa. 
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out, an artificial Ct of 40 was applied in order to include those values in the analysis. 
The following tables give an overview of the characteristics of gene expression. As 
visible in Table 5, only CD209 featured less than 80% detectable values. This 
censoring was considered for the statistical analysis. 
Characteristics of overall gene expression  
Share of detectable values 93.65% 
Share of non-detectable values 6.35% 
Censored values  8.5% 
Table 4: Descriptive display of overall gene expression. Non-detectable: Ct values >40. Censored values: 
exclusion because of known technical mistake. For one ID there was no sufficient material for 
measurement of gene expression in LpA stimulation (visible in the analysis as n=13 instead of n=14). 
Characteristics of gene expression per gene 
Candidate gene Share of non-detectable values Share of detectable values 
ATP2A3 1.53% 98.47% 
CALM2 0.59% 99.41% 
CD209 20.24% 79.76% 
FPR2 4.24% 95.76% 
IPS1 1.75% 98.25% 
ITPR2 0% 100% 
LY75 1.17% 98.83% 
ORAI1 2.99% 97.01% 
ORMDL3 0% 100% 
S100A8 0% 100% 
S100A9 0% 100% 
STIM2 2% 97.62% 
18S 0% 100% 
Table 5: Descriptive display of gene expression, sorted by candidate genes. Non-detectable: Ct values 
>40.
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4.2.2 Effect of stimulation 
The following figure illustrates the expression of the candidate genes after stimulation 
with either PHA or LpA compared to expression levels in unstimulated cord blood 
mononuclear cells (CBMCs) for the cohort that was analysed for this work.  
 
 
 
 
Fold change (log2 -   Ct) 
-1,5     0              2,5 5 8,4 
Figure 10: Graphic representation of fold change in comparison to unstimulated cells after stimulation for 
72h with PHA and LpA, respectively. Negative values (represented in green) show downregulation, 
positive values (represented in red) show upregulation. *** p<0,0001, ** p<0,001, *p<0,05 (t-test). PM 
persistent multitrigger, LOM late-onset multitrigger, PV persistent viral, TEV transient early viral, HC 
healthy controls. 
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4.2.4 Gene expression analysis in the wheeze subgroups 
For this paragraph the four subgroups multitrigger wheeze, persistent viral wheeze, 
transient early viral wheeze and healthy controls (see fig.8) were analysed. The 
results are organized in two parts, calcium signalling and innate signalling, according 
to the biological functions of each gene of interest. 
4.2.4.1 Expression of genes associated to calcium signalling 
4.2.4.1.1 Results for each gene 
In the following sections, the results for all calcium-related genes investigated in this 
work will be displayed, preceded by a short summary of the gene’s biological 
functions. 
 
 Inhibiting influence 
 
Gene or respective protein 
 
Activating influence  Second messenger 
Figure 11: Overview of the candidate genes in a schematic cell (light grey background). Genes related to 
calcium signalling are shown in grey boxes. Genes related to innate immunity are marked in bold.  
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4.2.4.1.1.1 ITPR2 
ITPR2 is a signal integrator that recognizes IP3, but also ROS and is located in the 
endoplasmatic reticulum. Upon activation, it initiates calcium release from the ER 
stores into the cytoplasm. 
 
Figure 12: Graphical representation of the results for ITPR2 in boxplots, sorted by stimulating condition 
on the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower ΔCT value 
as higher expression rate. * trend found in the comparison of the two indicated subgroups (p ≤ 0.1), ** 
significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two sample 
rank sum test.  
Differences between the four groups were seen in unstimulated cells, as the MT 
group showed a significantly higher expression of ITPR2 than the PV group (p= 
0.009). The same was visible in comparison of MT to healthy controls, but only as a 
trend (p= 0.09). After stimulation with PHA, this effect was strengthened in MT vs. HC 
(p=0.02) and remained significant for the comparison of MT vs. PV (p=0.01). Cells 
stimulated with LpA showed a significantly lower expression of ITPR2 in PV when 
compared to TEV (p=0.01) and a trend in the same direction when compared to 
healthy controls (p=0.06). 
**
p=0.02
**
p=0.009
*
p=0.09
**
p=0.01
**
p=0.01
*
p=0.06
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4.2.4.1.1.2 CALM2 
CALM2 is a receptor for elevated extracellular calcium levels located in the outer 
membrane of the cell. Its downstream signalling activates the NLRP3 inflammasome 
as well as the NFκB pathway through CALMKII. 
 
Figure 13: Graphical representation of the results for CALM2 in boxplots, sorted by stimulating condition 
on the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower ΔCT value 
as higher expression rate. * trend found in the comparison of the two indicated subgroups (p ≤ 0.1), ** 
significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two sample 
rank sum test. 
For CALM2, effects were only visible after PHA stimulation. The MT group showed a 
trend for higher gene expression when compared to TEV (p=0.06) and a significantly 
higher expression than the healthy controls (p=0.025).  
**
p=0.025
*
p=0.06
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4.2.4.1.1.3 ORAI1 
ORAI1 is part of a calcium channel in the outer cell membrane needed for store-
operated calcium entry after the depletion of the ER’s stores.  
 
Figure 14: Graphical representation of the results for ORAI1 in boxplots, sorted by stimulating condition 
on the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower ΔCT value 
as higher expression rate. * trend found in the comparison of the two indicated subgroups (p ≤ 0.1), ** 
significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two sample 
rank sum test.  
An elevated expression of ORAI1 for the MT group was already detected as a trend 
in unstimulated cells when compared to the persistent wheeze group (p=0.07). The 
same trend was visible in cells stimulated with PHA (p=0.06). For PHA stimulation, 
the MT group showed significantly higher expression in comparison with the TEV 
group (p=0.04) and trend wise in comparison with the healthy controls (p=0.09). In 
LpA, the persistent wheeze group showed significantly lowered expression opposed 
to the TEV group (p=0.03). 
**
p=0.03
*
p=0.06
*
p=0.07
**
p=0.04
*
p=0.09
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4.2.4.1.1.4 STIM2 
STIM2 is a protein located in the ER, sensing depletion of the ER’s calcium stores. If 
such depletion occurs, STIM2 initiates store-operated calcium entry. 
 
Figure 15: Graphical representation of the results for STIM2 in boxplots, sorted by stimulating condition 
on the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower ΔCT value 
as higher expression rate. * trend found in the comparison of the two indicated subgroups (p ≤ 0.1), ** 
significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two sample 
rank sum test.  
STIM2 was significantly higher expressed in the MT group when compared to the PV 
group (p=0.025), with the same effect visible as a trend in comparison to healthy 
controls (p=0.08), both in cells without stimulation.  
In PHA, the comparison MT vs. HC showed a significantly elevated expression of 
STIM2 in the multitrigger wheeze group (p=0.05). 
**
p=0.025
*
p=0.08
**
p=0.05
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4.2.4.1.1.5 ATP2A3 
ATP2A3 is a SERCA (sarcoplasmatic/endoplasmatic calcium ATPase) located in the 
ER and responsible for restoring physiological intracellular calcium levels after store-
operated calcium-entry.  
 
Figure 16: Graphical representation of the results for ATP2A3 in boxplots, sorted by stimulating condition 
on the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower ΔCT value 
as higher expression rate. * trend found in the comparison of the two indicated subgroups (p ≤ 0.1), ** 
significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two sample 
rank sum test.  
A trend for higher expression in the MT group compared to the TEV group was 
detected in cells stimulated with PHA (p=0.08). For PV vs. transient early viral 
wheeze in LpA there was significantly lower expression of ATP2A3 (p=0.04). 
*
p=0.08
**
p=0.04
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4.2.4.1.1.6 ORMDL3 
ORMDL3 is a protein responsible for inhibiting and thus controlling the SERCA 
ATP2A3. 
 
Figure 17: Graphical representation of the results for ORMDL3 in boxplots, sorted by stimulating 
condition on the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower 
ΔCT value as higher expression rate* trend found in the comparison of the two indicated subgroups (p ≤ 
0.1), ** significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two 
sample rank sum test. 
After PHA stimulation, expression of ORMDL3 was significantly higher in the MT 
group when compared to transient early viral wheeze (p=0.03). The same effect was 
visible as a trend in the MT vs. PV comparison (p=0.08). 
*
p=0.08
**
p=0.03
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4.2.4.1.1.7 S100A8 
S100A8 is a protein that is abundantly found in the cytoplasm of neutrophils. Upon 
activation of the neutrophil, it changes its location to the outer cell membrane. 
S100A8 has chemotactic functions, acts as DAMP and is involved in the cell redox 
state. However, through the liberation of arachidonic acid it also seems to have anti-
inflammatory properties.  
 
Figure 18: Graphical representation of the results for S100A8 in boxplots, sorted by stimulating condition 
on the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower ΔCT value 
as higher expression rate* trend found in the comparison of the two indicated subgroups (p ≤ 0.1), ** 
significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two sample 
rank sum test.  
For S100A8, neither significant effects nor trends were found in this analysis. 
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4.2.4.1.1.8 S100A9 
S100A9 is mainly found in complex with S100A8, and is then called calprotectin. It 
has similar functions as S100A8, but a less pronounced anti-inflammatory function 
than S100A8. 
 
Figure 19: Graphical representation of the results for S100A9 in boxplots, sorted by stimulating condition 
on the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower ΔCT value 
as higher expression rate* trend found in the comparison of the two indicated subgroups (p ≤ 0.1), ** 
significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two sample 
rank sum test.  
Significantly higher expression of S100A9 in cells stimulated with PHA was observed 
when the MT group was compared to healthy controls (p=0.05). 
**
p=0.05
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4.2.4.2 Expression of genes associated to innate signalling 
4.2.4.2.1 Results for each gene 
In the following sections, the results for all innate-immunity-related genes 
investigated in this work will be displayed, preceded by a short summary of the 
gene’s biological functions. 
 
Figure 20: Overview of the candidate genes in a schematic cell (light grey background). Genes shown in 
this paragraph, related to innate immunity, are marked in bold (FPR2, LY75, CD209 and IPS1). For a 
detailed legend see figure 11.  
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4.2.4.2.1.1 FPR2 
FPR2 is a protein in the outer cell membrane, acting as a PRR for bacterial signalling 
peptides and formylpeptide. Additionally, it recognizes lipoxins and is involved in IP3 
generation, thus contributing to the calcium-signalling pathway. 
 
Figure 21: Graphical representation of the results for FPR2 in boxplots, sorted by stimulating condition 
on the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower ΔCT value 
as higher expression rate* trend found in the comparison of the two indicated subgroups (p ≤ 0.1), ** 
significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two sample 
rank sum test.  
Trend wise, FPR2 expression was elevated in the MT group after stimulation with 
PHA, in comparison to both the PV and the TEV group (p=0.08 and p=0.06, 
respectively). In unstimulated cells, a trend for higher expression of FPR2 in the 
persistent viral wheeze group when compared to healthy controls was noticed 
(p=0.09). 
*
p=0.08
*
p=0.06
*
p=0.09
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4.2.4.2.1.2 IPS-1 
IPS-1 is a downstream adaptor signalling protein for other RIG-I-like-receptors, 
located in the mitochondrium. Upon activation, it influences the NFκB-pathway and 
leads to ROS generation.  
 
Figure 22: Graphical representation of the results for IPS1 in boxplots, sorted by stimulating condition on 
the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower ΔCT value as 
higher expression rate* trend found in the comparison of the two indicated subgroups (p ≤ 0.1), ** 
significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two sample 
rank sum test.  
IPS-1 expression was shown to be elevated in the MT group after PHA stimulation, 
significantly in comparison to the PV group (p=0.01) and as a trend in comparison to 
the TEV group (p=0.085). In addition, the TEV group showed a trend fhigher 
expression after LpA stimulation when compared to healthy controls (p=0.07). Also, 
in LpA-stimulated cells the expression of IPS-1 in the PV group was significantly 
lower than in the TEV group (p=0.01). 
**
p=0.01
**
p=0.01
*
p=0.07
*
p=0.085
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4.2.4.2.1.3 LY75 
LY75 is a PRR for cell death material for virally infected or apoptotic cells, located on 
the outer cell membrane. In a steady state, it has tolerance-inducing properties. 
 
Figure 23: Graphical representation of the results for LY75 in boxplots, sorted by stimulating condition on 
the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower ΔCT value as 
higher expression rate* trend found in the comparison of the two indicated subgroups (p ≤ 0.1), ** 
significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two sample 
rank sum test.  
Effects for higher expression in multitrigger wheeze were visible at a significant level 
in both unstimulated and PHA-stimulated cells (p=0.02 and p=0.01, respectively) 
when compared to the PV group. The same effect was visible as a trend in 
unstimulated cells (p=0.09) in comparison to the healthy controls. 
**
p=0.01
**
p=0.02
*
p=0.09
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4.2.4.2.1.4 CD209 
CD209 also is a PRR, detecting carbohydrates and Der-p, the main allergen of house 
dust mite. It can activate the arachidonic acid cascade and regulate the NFκB-
pathway via acetylation. 
 
Figure 24: Graphical representation of the results for CD209 in boxplots, sorted by stimulating condition 
on the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower ΔCT value 
as higher expression rate* trend found in the comparison of the two indicated subgroups (p ≤ 0.1), ** 
significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two sample 
rank sum test.  
For CD209, a significantly lowered expression after LpA stimulation in the persistent 
viral wheeze group when compared to the TEV group was observed (p=0.004). 
**
p=0.004
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4.2.5 In-depth analysis of the multitrigger group  
After comparing the four original, larger subgroups, a second analysis was 
conducted. The multitrigger group was divided in the three subtypes late-onset 
multitrigger (LOM), viral to multitrigger (VM) and persistent multitrigger wheeze (see 
fig.9). This was done because the MT group showed the most significant findings and 
by subdividing it, those effects could be traced back to the distinct subgroups causing 
them. However, due to the limited size of the multitrigger group (n=14), case 
numbers for this in-depth analysis were also small (n=2 for VM, n=4 for PM and n=8 
for LOM), meaning all results need to be interpreted with this limitation in mind. 
Again, the results are organized in two parts, calcium signalling and innate signalling, 
according to the biological functions of each gene of interest. Additionally, the 
changes in contrast to the analysis of the four original subgroups are commented on. 
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4.2.5.1 Expression of genes associated to calcium signalling 
4.2.5.1.1 Results for each gene 
In the following sections, the results from the in-depth analysis of the multitrigger 
wheeze subgroup for the calcium-related genes investigated in this work will be 
displayed, followed by a comment on the changes in regard to the analysis of the 
original four wheeze subgroups. In the interest of clarity, effects only concerning the 
PV, TEV and HC groups among one another are not shown in the figures. 
 
Figure 25: Overview of the candidate genes in a schematic cell (light grey background). Genes shown in 
this paragraph, related to calcium signalling, are marked in grey boxes (CALM2, ORAI1, ITPR2, STIM2, 
ATP2A3, ORMDL3, S100A8, S100A9). For a detailed legend see figure 11. 
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4.2.5.1.1.1 ITPR2 
For ITPR2, the previous effect in MT vs. PV for PHA stimulation changes to an effect 
in PM vs. PV. Also, new significant effects in LpA appear, both concerning the PM 
group. In regard to the comparison of MT to healthy controls, it can be seen that both 
the LOM and PM group were involved. However, the trend for higher expression in 
MT vs. HC in unstimulated cells disappears.  
 
Figure 26: Graphical representation of the results for ITPR2 in boxplots, sorted by stimulating condition 
on the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower ΔCT value 
as higher expression rate. * trend found in the comparison of the two indicated subgroups (p ≤ 0.1), ** 
significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two sample 
rank sum test.  
In unstimulated cells, effects were visible in the LOM group, significantly in 
comparison to PV (p=0.004) and as a trend in comparison to the healthy controls 
(p=0.06). A trend for higher expression in PHA when comparing the VM group to the 
PV group was noticed (p=0.07). Elevated expression in PHA for the comparison PM 
vs. PV (p=0.05) and PM vs. HC (p=0.05) were observed.  
In the PM group, expression was significantly higher in comparison to LOM (p=0.03) 
and PV (p=0.003) wheeze in LpA-stimulated cells. 
**
p=0.003
**
p=0.003**
p=0.05
**
p=0.05
*
p=0.07
**
p=0.004
*
p=0.06
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4.2.5.1.1.2 CALM2 
In this detailed analysis of the MT group, several trends for the whole MT group are 
strengthened to significant effects mediated by the PM group. Additionally, the 
different MT subgroups also differ amongst each other, namely the PM and the LOM 
subtype. Also, a new trend for LOM vs. TEV emerges in LpA.  
 
Figure 27: Graphical representation of the results for CALM2 in boxplots, sorted by stimulating condition 
on the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower ΔCT value 
as higher expression rate. * trend found in the comparison of the two indicated subgroups (p ≤ 0.1), ** 
significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two sample 
rank sum test.  
Most effects for CALM2 could be found in comparisons involving the PM group.  
In PHA, the persistent multitrigger group showed significantly higher expression than 
all the other groups (except VM): in comparison to LOM (p=0.02), to PV (p=0.02), to 
TEV (p=0.035) and to HC (p=0.008). In LpA, this effect was also visible as a trend 
when the PM group was compared to LOM (p=0.07).  
Additionally, the LOM group showed a tendency to lower expression than the TEV 
group (p=0.07) after LpA stimulation. 
**
p=0.02
*
p=0.07
**
p=0.02
**
p=0.035
**
p=0.008
*
p=0.07
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4.2.5.1.1.3 ORAI1 
In comparison to the four-group analysis, it emerges that effects previously attributed 
to the MT group can be traced to the PM group. In addition, one of the new 
significant effects is distinguishing the two MT subgroups PM and LOM through 
higher expression of ORAI1 in the PM group. The trend for higher expression in MT 
in comparison to HC after PHA stimulation disappears. 
 
Figure 28: Graphical representation of the results for ORAI1 in boxplots, sorted by stimulating condition 
on the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower ΔCT value 
as higher expression rate. * trend found in the comparison of the two indicated subgroups (p ≤ 0.1), ** 
significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two sample 
rank sum test.  
For ORAI1, the PM group showed high expression in all three stimulating conditions. 
In unstimulated cells, expression was trendwise higher than in the PV group 
(p=0.08). This effect was stronger in cells stimulated with LpA (p=0.002).  
In LpA, PM also showed significantly higher expression than the LOM group 
(p=0.02). After stimulation with PHA, higher expression than in the TEV group was 
observed (p=0.03).  Regarding trends, the ORAI1 expression in LOM was lowered in 
LpA when compared to TEV (p=0.09). 
**
p=0.02
*
p=0.08
**
p=0.002
*
p=0.09
**
p=0.03
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4.2.5.1.1.4 STIM2 
Here, a previously significant effect for MT vs. PV in unstimulated cells is divided into 
two trends concerning PM and LOM in comparison to PV. However, there are also 
new trends in comparisons involving the PM group, in both PHA and LpA. The 
significant effect of MT vs. healthy controls becomes a significantly higher expression 
in PM vs. HC.  
 
Figure 29: Graphical representation of the results for STIM2 in boxplots, sorted by stimulating condition 
on the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower ΔCT value 
as higher expression rate. * trend found in the comparison of the two indicated subgroups (p ≤ 0.1), ** 
significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two sample 
rank sum test.  
A trend for higher expression of STIM2 was observed in the comparison of PM vs. 
PV in all three stimulating conditions (unstimulated p=0.08, PHA p=0.06, LpA 
p=0.08). For PHA stimulation, the trend was also visible in PM vs. TEV (p=0.08). 
Also, PM showed significantly higher expression after PHA stimulation when 
compared to healthy controls (p=0.025). LOM showed higher expression of STIM2 in 
unstimulated cells than the PV group did (p=0.05) and a trend-wise higher expression 
than healthy controls (p=0.09). 
*
p=0.08
*
p=0.06
*
p=0.08
*
p=0.08
**
p=0.025
**
p=0.05
*
p=0.09
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4.2.5.1.1.5 ATP2A3 
Compared to the four-group analysis, the previous trend in MT vs. PV is 
strengthened to significance in PM vs. PV. Two new significant effects emerge for the 
LOM group, one of them distinguishing it from the PM group. 
 
Figure 30: Graphical representation of the results for ATP2A3 in boxplots, sorted by stimulating condition 
on the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower ΔCT value 
as higher expression rate. * trend found in the comparison of the two indicated subgroups (p ≤ 0.1), ** 
significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two sample 
rank sum test.   
In LpA, the persistent multitrigger group showed significantly higher expression than 
the LOM group (p=0.03) as well as the persistent viral group (p=0.02).  
The LOM group showed lower expression of ATP2A3 when compared to the TEV 
group (p=0.03). 
**
p=0.03
**
p=0.02
**
p=0.03
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4.2.5.1.1.6 ORMDL3 
In the in-depth analysis, there are many changes to the earlier analysis of the four 
wheeze subgroups. A new trend in unstimulated cells emerges for LOM vs. PV. 
Previously visible effects in PHA disappear (MT vs. PV and MT vs. TEV). Instead, 
new effects in LpA appear, both of them involving the PM group.  
 
Figure 31: Graphical representation of the results for ORMDL3 in boxplots, sorted by stimulating 
condition on the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower 
ΔCT value as higher expression rate. * trend found in the comparison of the two indicated subgroups (p ≤ 
0.1), ** significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two 
sample rank sum test.  
For ORMDL3, expression in cells stimulated with LpA was significantly higher in the 
PM group as opposed to the PV group (p=0.02), a trend also visible in comparison to 
healthy controls (p=0.08).  
In unstimulated cells, the late-onset multitrigger group showed a trend higher 
expression than the PV group (p=0.07). 
**
p=0.02
*
p=0.08
*
p=0.07
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4.2.5.1.1.7 S100A8 
While in the four-group comparison there were neither trends nor significant effects 
for S100A8, in this more detailed analysis of the MT group three new effects 
concerning late-onset multitrigger group emerge for cells stimulated with LpA.  
 
Figure 32: Graphical representation of the results for S100A8 in boxplots, sorted by stimulating condition 
on the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower ΔCT value 
as higher expression rate. * trend found in the comparison of the two indicated subgroups (p ≤ 0.1), ** 
significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two sample 
rank sum test.  
The LOM group showed a trend for lower S100A8 expression than the TEV group 
(p=0.07) as well as the PV group (p=0.06). In comparison to healthy controls, 
S100A8 expression is significantly lower in the LOM group (p=0.04).  
*
p=0.06
*
p=0.07
**
p=0.04
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4.2.5.1.1.8 S100A9 
Parallel to S100A8, a new effect concerning expression in LOM group after LpA 
stimulation appears in this analysis. However, a previously significant effect for MT 
vs. HC diminishes to a trend. Additionally, a new significant effect distinguishing the 
LOM group from the persistent multitrigger group emerges. 
 
Figure 33: Graphical representation of the results for S100A9 in boxplots, sorted by stimulating condition 
on the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower ΔCT value 
as higher expression rate. * trend found in the comparison of the two indicated subgroups (p ≤ 0.1), ** 
significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two sample 
rank sum test.  
In PHA, there is a trend for higher expression of S100A9 in PM when compared to 
healthy controls (p=0.08).  
In LpA, the TEV group shows higher expression than the LOM group (p=0.03). Also, 
in the comparison PM vs. LOM, the persistent multitrigger group has a higher 
expression (p=0.004). 
**
p=0.004
*
p=0.08
**
p=0.03
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4.2.5.2 Expression of genes associated to innate signalling 
4.2.5.2.1 Results for each gene 
In the following sections, the results from the in-depth analysis of the multitrigger 
wheeze subgroup for the innate-immunity-related genes investigated in this work will 
be displayed, followed by a comment on the changes in regard to the analysis of the 
original four wheeze subgroups. In the interest of clarity, effects only concerning the 
PV, TEV and HC groups among one another are not shown in the figures.  
 
 
Figure 34: Overview of the candidate genes in a schematic cell (light grey background). Genes shown in 
this paragraph, related to innate immunity, are marked in bold (FPR2, LY75, CD209 and IPS1). For a 
detailed legend see figure 11. 
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4.2.5.2.1.1 FPR2 
For FPR2, trends already visible in PHA for the whole MT group changed to 
significant differences in the PM group. In addition, new effects appear for cells 
stimulated with LpA, one of them differentiating the LOM from the PM group. Also, a 
new trend concerning the comparison LOM vs. TEV in LpA-stimulated cells emerges. 
 
Figure 35: Graphical representation of the results for FPR2 in boxplots, sorted by stimulating condition 
on the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower ΔCT value 
as higher expression rate. * trend found in the comparison of the two indicated subgroups (p ≤ 0.1), ** 
significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two sample 
rank sum test.  
In PHA, there is a significantly higher expression in the PM group when compared to 
persistent viral wheeze (p=0.008) as well as compared to transient early viral wheeze 
(p=0.03). Similarly, in LpA the PM group showed elevated expression in comparison 
to the LOM group (p=0.03) and to the PV group (p=0.025), as well.  
In LpA there was also a trend for lower FPR2 expression in the LOM group when 
compared to the TEV group (p=0.09). 
**
p=0.03
**
p=0.025
**
p=0.008
**
p=0.03
*
p=0.09
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4.2.5.2.1.2 IPS-1 
For IPS-1, several new effects involving the PM group emerge for LpA- as well as 
PHA- stimulated cells. A new effect differentiating the LOM group from the TEV 
group was discovered. 
 
Figure 36: Graphical representation of the results for IPS1 in boxplots, sorted by stimulating condition on 
the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower ΔCT value as 
higher expression rate. * trend found in the comparison of the two indicated subgroups (p ≤ 0.1), ** 
significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two sample 
rank sum test.  
In general, the persistent multitrigger group showed the highest expression in this 
comparison. In LpA, expression of IPS-1 in PM was significantly higher than in the 
PV group (p=0.01) as well as the healthy controls (p=0.025). Trend-wise, this effect 
was also noticeable in the comparison PM vs. LOM (p=0.07). In cells stimulated with 
PHA, parallel effects were observed: IPS-1 expression was higher in PM than in the 
PV group (p=0.008), and higher than in the TEV group, although only as a trend 
(p=0.08). Also, the LOM group showed a lower expression than the TEV group after 
LpA-stimulation (p=0.03). 
*
p=0.07
**
p=0.01
**
p=0.008
*
p=0.08
**
p=0.025
**
p=0.03
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4.2.5.2.1.3 LY75 
In comparison to the previous analysis, multiple new effects showing a higher 
expression emerge for the PM group in cells stimulated with PHA as well as in cells 
after LpA-stimulation. Additionally, there are new effects visible in unstimulated cells 
for the comparison LOM vs. PV and healthy controls.  
 
Figure 37: Graphical representation of the results for LY75 in boxplots, sorted by stimulating condition on 
the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower ΔCT value as 
higher expression rate. * trend found in the comparison of the two indicated subgroups (p ≤ 0.1), ** 
significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two sample 
rank sum test.  
In LpA, the PM group showed significantly higher expression than both LOM (p=0.01) 
and PV (p=0.05). In PHA, exactly the same effect was visible for both the 
comparisons PM vs. LOM (p=0.01) and PM vs. PV (p=0.003). Additionally, LY75 
expression in the PM group was significantly elevated when compared to healthy 
controls (p=0.015). As a trend, higher expression in PM in comparison to the TEV 
group was observed (p=0.06). In unstimulated cells, expression of LY75 in the PM 
group compared to the persistent viral wheeze group was significantly elevated 
(p=0.02). There was a parallel trend in LOM vs. healthy controls (p=0.08).  
**
p=0.05
**
p=0.01
**
p=0.01
**
p=0.003
*
p=0.06
**
p=0.015
**
p=0.02
*
p=0.08
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4.2.5.2.1.4 CD209 
In contrast to the analysis of the original four wheeze subgroups new, partly 
significant effects appeared for cells after stimulation with LpA appeared, involving 
the PM as well as the LOM group. 
 
Figure 38: Graphical representation of the results for CD209 in boxplots, sorted by stimulating condition 
on the x-axis and by phenotype as indicated in the legend. Y-axis inverted to illustrate a lower ΔCT value 
as higher expression rate. * trend found in the comparison of the two indicated subgroups (p ≤ 0.1), ** 
significant findings in the comparison of the two indicated subgroups (p ≤ 0.05) for Wilcoxon two sample 
rank sum test.  
In the PM group, CD209 expression was significantly higher than in PV (p=0.03) and 
trend-wise higher than in the LOM group (p=0.07) in cells stimulated with LpA. Also, 
in LpA, expression of CD209 was lower in the LOM group when compared to 
transient early viral wheeze (p=0.016). 
 
*
p=0.07
**
p=0.03
**
p=0.016
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5 Discussion 
Despite great efforts in research, asthma remains one of the most common chronic 
diseases in childhood, developing already early in life. To improve the current 
situation of asthma patients, which is severely lacking in many dimensions, new, 
targeted, more effective therapeutic strategies and predictive tools are urgently 
needed [169]. However, to identify possible targets for therapy as well as to correctly 
deliver individualized therapy to the patients, it is necessary to define precise and 
consistent asthma endotypes.  
This thesis investigated the gene expression of immunological pathways in cord 
blood mononuclear cells. In combination with the detailed follow-ups of the study 
population, this study seeks to identify possibly pathogenetic gene expression 
patterns within the immune system. A long-term goal could be the development of 
selected candidate genes as new biomarkers that could possibly be used to predict 
the outcome of childhood asthma. 
In the following paragraphs, the results will be discussed against the background of 
the current state of relevant studies. 
5.1 Overview of the main findings 
In CBMC samples selected from the PAULINA/PAULCHEN birth cohort, expression 
of all candidate genes could be detected via qRT-PCR. While gene expression in 
CBMCs is often only detectable after stimulation, in this study all candidate genes 
could be detected even in unstimulated cells. Expression varied, trend-wise and 
significantly, among the subsets of children with transient early viral, persistent viral 
or multitrigger wheeze, and also in comparison to healthy controls. Despite the small 
sample size (n=14 per group, lower for the in-depth analysis of the multitrigger 
group), highly significant differences in gene expression levels could be detected. 
Even so, this limitation needs to be kept in mind when interpreting the results from 
this work. 
What sets apart these results is the fact that instead of single findings for stand-alone 
genes with often only mild impact on phenotypes, consistent patterns of elevated or 
lowered gene expressions could be detected for a whole signalling pathway [35].  
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5.1.1 Main findings for transient early viral wheeze 
Gene expression patterns for transient early viral wheeze showed a level of gene 
expression below that of persistent multitrigger wheeze, visible in significant effects 
for FPR2, CALM2 and ORAI1 as well as in trend-wise effects for LY75, STIM2 and 
IPS1, all after stimulation with PHA. In comparison to persistent viral wheeze, TEV 
wheeze showed significantly higher expression of ITPR2, CD209, ORAI1, ATP2A3 
and IPS1, all visible after stimulation with LpA. This gene expression pattern is 
mostly parallel to that of healthy controls. This theory was tested in a three-group 
comparison9 merging HC and transient early viral wheeze (TEV).  
These findings fit the description of transient early wheeze in other studies as very 
common and associated with viral infection but unrelated to atopy, generally 
disappearing without any intervention [170, 171].  
Accordingly, cohort studies have shown a good prognosis in terms of wheeze 
frequency in later childhood. Martinez et al. reported that 60% of children who 
experienced viral wheeze until their third birthday outgrow their symptoms by age 6 
[12]. Additionally, a follow-up study to the Tucson birth cohort proposed children who 
wheezed before age three but not at age six were shown to be as unlikely to 
experience wheeze again after age six as children who had never wheezed [172]. 
Children with TEV wheeze have been consistently reported to have impaired lung 
function in infancy. However, lung function in later childhood has been controversially 
discussed as it had recovered when the children reached school age in some 
cohorts, whereas it stayed at a comparatively low level in others [12, 173]. 
Still, the major part of children who wheeze transiently early in life have a good 
prognosis in terms of respiratory function and show no clinical symptoms at school 
age [174-177].  
 
Results from this study indicate that TEV wheeze does not show altered gene 
expression levels at birth, neither in genes related to calcium signalling nor antiviral 
innate immunity. However, these children still experience wheeze. A possible 
explanation might be the involvement of other pathogenetic factors besides immune 
regulation at birth. Consistently being reported as risk factor is smoking during 
pregnancy. Some studies propose a direct influence of in-utero smoke exposure 
through impaired lung growth and maturation resulting in congenitally smaller 
 
9 As there were no vast differences to the conducted four-group analysis, these data are not shown. 
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airways, a predisposition for wheeze while others suggests it is mediated through 
lower birth weight [38, 178-180]. However, in this study smoking during pregnancy 
could be excluded as possible confounder, pointing out that this theory might only be 
true in some cases. Other influencing factors reported for TEV wheeze include the 
mother’s vitamin D status as potentially protective through the development of the 
foetal lung and thus wheeze as well as a potential influence of young maternal age 
and high maternal BMI [181, 182]. While no evidence for this as an influence through 
socioeconomic status could be found in this study, it has also been proposed that the 
in-utero exposure to systemic inflammation in obesity can hinder the development of 
the child’s immune system [180, 183]. The importance of immune maturation is 
underlined by studies that showed exposure to animal sheds on farms lowers the risk 
for TEV wheeze, suggesting that early life exposure to diverse bacteria could hold an 
immunomodulatory protective effect [184]. 
 
In summary, findings from this work indicate that transient early viral wheeze has a 
gene expression level similar to that of healthy controls. This indicates a positive 
outlook for these children as there seems to be no underlying major modification in 
immune regulation at play.  A hypothesis as to why TEV patients experience wheeze 
anyway that would be consistent with findings from this study is that multiple 
potentially modifiable influences lead to a limited period of susceptibility to lower 
respiratory tract infection. This in turn causes oedema, effectively diminishing the 
already small airway diameter of these children, resulting in wheeze [12, 17, 185-
187]. 
As transient early wheeze currently can only be defined to have been transient in 
retrospect, most of the patients in this group are treated with ICS, accounting for the 
major part of ICS prescriptions in preschool children. However, the benefit of ICS for 
these patients is minimal, as they have been shown to be likely to remit without 
intervention eventually. As ICS have grave side effects like growth retardation, this is 
not to be taken lightly [173, 188]. A way to, indirectly, improve therapeutic 
management of these children through the findings of this work could lie in early 
identification of children at risk for persistent wheeze, which will be discussed in the 
following paragraphs. 
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5.1.2 Main findings for persistent viral wheeze  
 
Figure 39: Overview of the significant findings for persistent viral wheeze, based on differences in Ct 
values. HC healthy controls, TEV transient early viral wheeze, PV persistent viral wheeze, PM persistent 
multitrigger, LOM late-onset multitrigger, MT multitrigger. Red background marks higher expression, 
green background marks lower expression. All subgroups indicated in the grey boxes have been 
compared to persistent viral wheeze. * trend like results (p ≤ 0,1); ** significant results (p ≤ 0,05). 
Stimulating conditions can be seen next to the level of significance: 1 unstimulated, 2 
phytohemagglutinin, 3 lipid A. For a detailed legend see chapter 9.5 in the appendix. 
Children with persistent viral wheeze showed an overall trend for a low level of 
expression of the candidate genes with varying levels of significance depending on 
the respective subgroup comparison. The only exception to this overall pattern is a 
trend for higher expression of FPR2 in healthy controls. 
A large number of candidate genes – including CALM2, ITPR2, ORAI1, STIM2, 
ATP2A3, ORMDL3, IPS1, LY 75 and CD209 - show significantly lower expression in 
children with persistent viral wheeze in comparison to persistent multitrigger wheeze, 
after both stimulation with LpA and PHA, respectively. In comparison to late-onset 
multitrigger wheeze, PV showed significantly lower expression of ITPR2 and STIM2 
as well as a trend-wise lower expression of ORMDL3 and LY75 in unstimulated cells.  
The effects distinguishing PV from TEV wheeze have already been in summarized in 
the chapter above, but fit with the overall pattern of lower expression of the candidate 
genes in persistent viral wheeze. 
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As discussed above, it is important to single out children at risk for persistent wheeze 
from the larger pool of children that experience wheeze before the age of three. As 
most transient early wheeze episodes are connected to viral infection, it is of special 
interest to identify mechanisms that distinguish between transient early viral and 
persistent viral wheeze. A possible predictive pattern that has been identified is that 
children with “troublesome early viral” wheeze are likely to also show viral wheeze at 
age six, which fits description of persistent viral wheeze used in this work [189]. 
Troublesome, in this case, means severe forms of early viral wheeze. Consistently, in 
other studies children with wheeze caused by severe bronchiolitis that required 
hospitalization before the age of three have been shown to be at high risk to develop 
recurrent and persistent wheeze and subsequent asthma [190, 191]. The comparison 
TEV vs. PV wheeze from this work show lower expression of genes related to innate 
antiviral immunity in PV wheeze, such as IPS1 or CD209, after stimulation with LpA.  
Additionally, several genes in the calcium signaling pathway, such as ITPR2, 
ATP2A3 and ORAI1 show the same pattern. ITPR2, for example, is a central signal 
integrator at the starting point of the calcium signaling pathway, so a diminished 
expression, and eventually an impaired function could potentially cause disturbances 
in the whole signaling pathway [105]. Hypothetically, this impaired response could 
facilitate more severe and recurrent infections, in accordance with the reports of 
severe early viral wheeze being a possible precursor of persistent viral wheeze [175].  
 
It has been repeatedly proposed that an important part of PV wheeze pathogenesis 
lies in aberrant stabilization in response to recurrent viral infection and delayed 
maturation of the immune system, especially of Th1-type immunity. This results in a 
susceptibility for lower respiratory tract infections that create airway inflammation, 
disturbing the postnatal maturation or development of the respiratory system [2, 187, 
192]. In keeping, other reports show that physiologically, innate immune cells are 
kept in an “alerted state” through exposition to bacteria in order to be ready to ward 
off viral infections through the release of IL-1 when sensing an inflammasome 
trigger. The authors suggest that impairment of these mechanisms, either through 
not enough exposition to bacteria or through altered function of the inflammasome 
and its triggers could result in a reduced capacity to clear viral infection, contributing 
to the susceptibility to lower respiratory tract infection in persistent viral wheeze [193].  
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Results from this work show altered gene expression for several genes connected to 
inflammasome function, albeit in a small sample and different subgroup comparisons, 
as visualized in fig. 39. The most interesting results for a candidate gene from this 
work come from ITPR2, for which PV wheeze showed significant or trend-wise 
lowered expression of ITPR2 in comparison to all other subgroups. As described 
above, ITPR2 holds a central role in the calcium signalling pathway that regulates the 
intracellular level of calcium ([Ca2+]i). A high [Ca2+]I has been reported to activate the 
inflammasome, so hypothetically disturbances in the pathway controlling [Ca2+]i could 
lead to impared function of the inflammasome [138, 140]. The same gene expression 
pattern is also visible for other genes of the calcium signalling pathway such as 
STIM2, ORAI1, ATP2A3 and ORMDL3, albeit less pronounced.  
The underlying causes for this pattern need to be investigated further, primarily in a 
larger sample. Still, the results from this work indicate the possibility that an impaired 
innate immune response plays a central role to uncovering why children with PV go 
on to have infection-associated symptoms after three years of age [194, 195]. 
 
Virus-induced wheeze episodes have been shown to fulfil all main characteristics of 
asthma which strongly suggests the existence of a childhood asthma phenotype that 
develops from persistent viral wheeze [196]. Indeed, the phenotype persistent viral 
wheeze has been described as predominantly unrelated to atopy and with relatively 
normal lung function, with the majority of children outgrowing their symptoms during 
early school years [186, 197]. In other studies, however, persistent viral wheeze has 
been described as a risk factor for a rapid decline in lung function in adult patients 
even in the absence of asthma. An impaired development of the airways, preventing 
these patients from reaching full lung function, could be a possible explanation for 
these opposing results. As lung function peaks at age 25, a low performance might 
not immediately be visible, explaining the relatively normal lung function at school 
age [38, 198]. 
Supporting the concept of persistent viral wheeze as a distinct phenotype, an atopy-
independent pathway for asthma genesis that begins as early as in utero has been 
proposed as profiles of antiviral cytokines from non-asthmatic mothers during 
pregnancy relate at least partly to the child’s asthma risk [199]. This suggests a 
distinct pathophysiologic mechanism through which viral infection leads to wheeze 
rather than the effect being mediated through the development of atopy, clearly 
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differentiating viral from multiple-trigger wheeze [200]. As visible in fig. 39 and as 
already mentioned above, this work shows a distinct gene expression signature for 
persistent wheeze that is clearly distinguishable from the other wheeze subgroups 
that were analysed, especially from persistent multitrigger wheeze. While these 
results, despite their high significance levels, need to be interpreted with caution due 
to sample size, they too point in the direction of a distinct childhood asthma 
phenotype that develops from persistent viral wheeze. 
 
However, the definition of multiple-trigger wheeze also includes wheeze during viral 
infection. This, at first glance, seems contradictory, however recent research 
proposed an explanation through the type of virus infection. The two most common 
viral infections in childhood are rhinovirus (RV) infection, which has been linked to 
multitrigger wheeze, and respiratory syncytical virus (RSV) infection, linked to 
persistent viral wheeze. Both have been shown to interfere with innate immune 
responses [193]. Rhinovirus infection has been linked to multiple trigger wheeze, as 
infection under the age of three has been shown to be a risk factor for wheeze 
development. Additionally, it shows a strong link to subsequent childhood asthma, 
with one mechanism possibly linked to the susceptibility locus 17q21 in an interesting 
gene-environment-interaction proposition, and another to allergic sensitization [42, 
201, 202]. As to persistent viral wheeze, studies have shown that while maternal 
atopic asthma is a risk factor for rhinovirus induced wheeze, it did not influence RSV 
induced wheeze [202, 203]. This fits with the emerging role of respiratory syncytical 
virus for the pathogenesis of persistent viral wheeze. Early life RSV infection, 
especially when so severe it requires hospitalization have been associated with 
recurrent wheezing in several studies and has already been discussed above [204]. 
 
As of yet, there is no specific treatment for rhinovirus infection, and whether 
corticosteroids can positively influence the resulting airway inflammation is unclear 
[83]. This, however, is different for respiratory syncytical virus infection.  
A possible treatment that may even prevent the development of persistent viral 
wheeze, might lie in reducing RSV-related lower respiratory tract infections. In 
continuation of this hypothesis, this would in turn lead to reduced frequency of 
wheeze episodes in the first years of life, and has already been shown to be effective 
in reducing the need for asthma medications [170, 193, 202]. 
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As especially RSV infections occur in the first few months of life, identifying children 
at risk already at birth could prove very valuable for these patients. Even if the 
progression to childhood asthma cannot be stopped, early identification could for 
example lead to closer clinical monitoring and maybe intermittent ICS therapy to 
alleviate morbidity for patients with persistent viral wheeze [205]. 
In summary, results from this work showed evidence for a transcriptional signature of 
persistent viral wheeze with low expression of genes important for antiviral immunity 
as well as calcium signaling that is closely related to the functions of innate immunity, 
directly visible at birth. These results indicate that further investigation of gene 
expression patterns at birth, for example in a larger cohort with additional follow-up 
information regarding RSV infection, could add to early identification of these patients 
in order to improve clinical management.  
 
5.1.3 Main findings for multitrigger wheeze 
In children presenting multitrigger wheeze, the majority of the candidate genes, 
whether associated with the immunological pathways of calcium signalling or innate 
antiviral immunity, are significantly upregulated in comparison to healthy controls and 
other wheeze subgroups. Significantly or trend-wise upregulated genes include 
ITPR2, CALM2, ORAI1, STIM2, ORMDL3, S100A9, IPS-1 and LY75. This 
upregulation was partly detectable in unstimulated cells and mostly in cells after 
stimulation with PHA, with some effects also showing after stimulation of the innate 
immune system with LpA.  
Multiple-trigger wheeze in preschool children has consistently been proposed to be a 
phenotype at high risk for progression to allergic asthma [206]. Accordingly, it has 
been linked to lower lung function and a higher risk for atopy [207, 208].  
Children with atopic asthma have been shown to have continuous airway 
inflammation while the same was not found in children with virally-induced wheeze. 
This suggests the existence of an inflammatory mechanism in MT wheeze that is 
permanently present, for example through a genetic predisposition for atopy that 
leads to allergic airway inflammation [209]. 
However, therapeutically targeting the known mechanisms of allergic airway 
inflammation, for example through specific antibodies, has so far fallen short of 
expectations. As it has already been explained in detail in the introduction (see 
chapter 1.4), this challenge has been one of the incentives to pursue endotyping as 
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the differences in clinical presentation most likely result from different pathogenetic 
mechanisms [13].  
With this in mind, the multitrigger group was divided in the three subtypes late-onset 
multitrigger (LOM), viral to multitrigger (VM) and persistent multitrigger wheeze (see 
fig.9) for a second analysis. Viral to multitrigger wheeze was included in this analysis 
because in general, wheeze persistence does not necessarily mean the same 
pathophysiological reason remains. In this example of a longitudinal pattern, children 
wheeze because of impaired antiviral immunity early in life and then later because of 
atopic sensitization [210]. However, for the latter there was not enough power for 
reliable analysis due to small sample size, so the following paragraphs will focus on 
persistent and late-onset multitrigger wheeze.  
This already illustrates the main challenge of this in-depth analysis, as due to the 
limited size of the multitrigger group (n=14), case numbers for this in-depth analysis 
were also small (n=2 for VM, n=4 for PM and n=8 for LOM), meaning the following 
discussion of the findings need to be interpreted with this limitation in mind. Even so, 
results from this work show significant results that point to the existence of separate 
endotypes for multitrigger wheeze that are clearly distinguishable through their 
longitudinal pattern as well as their gene expression signature. 
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5.1.3.1 Findings for persistent multitrigger wheeze 
 
Figure 40: Overview of the significant findings for persistent viral wheeze, based on differences in Ct 
values. HC healthy controls, TEV transient early viral wheeze, PV persistent viral wheeze, PM persistent 
multitrigger, LOM late-onset multitrigger, MT multitrigger. Red background marks higher expression, 
green background marks lower expression. All subgroups indicated in the grey boxes have been 
compared to persistent multitrigger wheeze. * trend like results (p ≤ 0,1); ** significant results (p ≤ 0,05). 
Stimulating conditions can be seen next to the level of significance: 1 unstimulated, 2 
phytohemagglutinin, 3 lipid A. For a detailed legend see chapter 9.5 in the appendix. 
Within the multitrigger wheeze group as well as the whole cohort selected for this 
work, the group with persistent multitrigger wheeze showed the most distinct gene 
signature with a high level of expression of the candidate genes, visible for ITPR2, 
CALM2, ORAI1, STIM2, ATP2A3, ORMDL3, IPS1, LY75, CD209 and FPR2. Despite 
the small sample size of n=4, the findings were highly significant, emphasizing their 
importance. This pattern, as illustrated in fig. 40, was predominantly visible after 
stimulation and for the majority of the candidate genes, both those associated to the 
immunological pathways of calcium signalling and to innate immunity, in different 
subgroup comparisons. LY75 as well as IPS1 are of special interest because the 
elevated gene expression pattern was significant or trend-wise significant in 
comparison to all other subgroups, although after different stimulating conditions. The 
most interesting effects are visible for CALM2, which shows significantly elevated 
expression in contrast with all other subgroups after PHA stimulation.  
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Children with multitrigger wheeze already at one to three years of age have been 
shown to have a high level of IgE during the first year of life. This sets atopy down as 
a strong predictor for persistent wheezing and subsequent asthma development, as 
wheeze patterns and lung function that are established at age six are relatively stable 
until young adulthood [170, 172]. Among high IgE levels, other atopic manifestations 
like atopic dermatitis and food allergy have been shown to be predictors for wheeze 
persistence [211]. The presence of atopy in asthma has been connected to severe 
asthma, with studies suggesting that atopy associated pathways additionally increase 
the severity of viral exacerbations [212, 213]. Children with severe asthma have been 
described as severely atopic with multiple aeroallergen sensitization [214]. Taken 
together with findings that asthma severity is established early in life, this adds to the 
hypothesis that persistent multitrigger wheeze could be the precursor of a severe 
asthma phenotype later in life [45].  
 
However, eosinophilic inflammation that traditionally is considered as hallmark 
feature of allergy is only found in roughly half the patients with severe asthma, 
indicating the presence of another pathogenetic mechanism, such as for example 
neutrophilic airway inflammation, or mixed airway inflammation in which eosinophilic 
and neutrophilic inflammation are present [12, 187, 215-217].  
In general, the results from this work support a genetic influence visible in 
upregulated expression of the candidate genes as important factor in the 
pathogenesis of persistent multitrigger wheeze, as well as the role of the IL-1-
pathway and its link to neutrophilic airway inflammation [218].  
 
The finding of such a distinct gene expression signature for persistent multitrigger 
wheeze in this work suggests the possible existence of a distinct endotype for this 
group even though the small sample size limits the reliability of these data.  
However, the theory of PM wheeze as a distinct endotype, potentially driven by 
neutrophilic inflammation, with a strong genetic signature is supported for example by 
Yeh et al. who demonstrated the existence of a distinct gene expression signature in 
PBMCs of children that were classified as neutrophilic severe asthmatics [219]. Other 
studies found evidence of transcriptional signatures that distinguished inflammatory 
phenotypes (eosinophilic and neutrophilic vs. less severe) in induced sputum from 
adult asthmatics, or controlled from severe asthma in schoolchildren. However, in 
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terms of early identification for predictive purposes, induced sputum and airway 
epithelial brushings, used in these studies, are impractical especially in younger 
children, highlighting the importance of gene expression profiling [216]. 
Consistently, the candidate genes chosen for this work relate to neutrophilic 
inflammation mainly through the influence of calcium on the NLRP3-Inflammasome 
and subsequently, the IL-1-pathway. Upregulated expression of candidate genes 
such as CALM2, ITPR2, ORAI1, STIM2 all lead to an increased level of intracellular 
calcium and thus inflammasome activation [140]. Additionally, differential gene 
expressions also included influences on the NFB pathway for example through 
elevated expression of IPS1, responsible for the translocation of NFB to the nucleus 
and thus controlling its activity [144]. Both pathways have also previously been 
connected to innate activation in asthma patients with neutrophilic airway 
inflammation [220-223].  
 
Even though the candidate genes predominantly show a functional relation to 
neutrophilic inflammation as opposed to eosinophilic inflammation, persistent wheeze 
in general has repeatedly and strongly been associated with parental allergy [12, 
180, 224]. Additionally, a family predisposition for asthma has been shown in several 
studies, often linked to maternal asthma. Studies also shown that asthma increases 
for children who have two parents with asthma [225]. A large study by Ferreira et al. 
investigated this overlap of asthma and allergy and found shared genetic variations 
between both with possible functional relevance [226]. 
Even so, by far not all atopic children go on to develop asthma. An intriguing model 
explaining this sees the impact of allergic sensitization on asthma development as 
not binary but quantitative, with relevant influences being the time of sensitization 
and number of sensitized aeroallergens [227]. Early allergic sensitization to multiple 
aeroallergens that persists during childhood has been repeatedly identified as 
important risk factor for wheeze persistence and asthma inception as well as loss of 
lung function [171, 186, 187, 197, 228]. Together with recent results that show that 
allergic sensitization assessment can predict exacerbation rates and response to ICS 
therapy in children with persistent, recurring wheeze, reinforces the involvement of 
atopy in the development of multitrigger wheeze [229]. Consistently, the phenotype 
definition of multitrigger wheeze used for this work included parent-reported or 
doctor-diagnosed allergic comorbidities as well as positive allergy testing. 
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This conflicting information about the known characteristics of persistent multitrigger 
wheeze from other studies pose a main challenge in the interpretation of the findings 
from this work. On the one hand, persistent multitrigger wheeze is consistently 
closely connected to atopy and allergic, eosinophilic inflammation. On the other 
hand, the expression pattern of the candidate genes and other phenotypes with 
equally distinct gene expression signatures suggest it at least has features of 
neutrophilic inflammation. 
It is possible that the answer is a combination of both with a pathogenetic 
involvement of both innate and adaptive immunity. Traditionally, atopy has always 
been assigned to adaptive immunity. However, since the discovery of the farm effect 
that links innate immune stimulation to reduced incidence of allergic disease, this has 
changed [5]. Recent studies highlight the importance of innate immunity in atopy 
through of ILC2 that produce type 2 cytokines and have been shown to drive airway 
inflammation in response to allergic sensitization, especially in paediatric patients 
with severe asthma [187, 230-232]. A study by Stadhouders et al. showed that ILCs 
also express genes known for their role in the pathogenesis of especially allergic 
asthma such as ORMDL3, highlighting their pathogenetic role and thus linking the 
innate immune system to allergic disease [233]. Consistently, data for PM wheeze 
from this work show an elevated expression of ORMDL3, for example in comparison 
to persistent viral wheeze.  
The gene expression signature for persistent multitrigger wheeze that was found in 
this work includes candidate genes from calcium signalling as well as from innate 
immunity. Calcium signalling is important in adaptive immunity, for example through 
signal transduction after the stimulation of the TCR, as well as in innate immunity as 
shown through its influence on the IL-1-pathway. The innate immunity receptors 
analysed in this work also have points of interaction to adaptive immunity and allergy, 
as for example CD209 and LY75 that have tolerance-inducing capacities that, if 
disrupted, lead to an increased risk of allergy.  
With all this in mind, it seems possible that persistent multitrigger wheeze could be 
the result of a combination of atopy and predominantly neutrophilic inflammation as 
two main pathogenetic pathways. However, this is purely hypothetical as the sample 
size in this work was too small to allow any ultimate conclusions. 
 
 85 
Currently most children with preschool multitrigger wheeze or subsequent (allergic) 
childhood asthma are treated with different forms of corticosteroids. However, even 
early initiation of ICS treatment does not prevent progression from preschool wheeze 
to childhood asthma. [187, 234]. This could be explained by the fact that ICS 
treatment is often started only after the occurrence of symptoms whereas the loss of 
lung function and genetic signature are already visible much earlier, i.e. at birth, as it 
was shown in this work. Additionally, the linkage of atopy to the innate immune 
system as proposed above could provide further explanation for this problem, as the 
innate immune system is intrinsically non-reacting to steroids. This underlines the 
importance of more diversely targeted therapeutic strategies [234, 235]. For example, 
studies have tried to target the avoidance of allergen sensitization with different 
levels of success, at the moment, the most promising approach seems to be early 
allergen immunotherapy [170, 236, 237].   
Even where targeted therapies already exist, the next obstacle is to bring them to the 
right patients, a goal described as precision medicine [187, 238, 239]. The results 
from this work, after careful validation, could for example one day support precision 
medicine through a score supported by transcriptional signatures in cord blood with 
the goal of early identification of children that are at risk for persistent multitrigger 
wheeze. The importance of early identification is highlighted by findings that 
approximately 40% of lung function loss in children who show persistent wheeze at 
age 7 was already present at birth, and that this group benefits from therapy to 
maximize lung function [234, 240].  
 
In summary, the results presented in this work support the existence of a high-risk 
transcriptional endotype that leads to the phenotype of persistent multitrigger wheeze 
that is already identifiable at birth. Data from this work also indicate that PM might be 
established through several pathogenetic pathways, with possible pathways in atopy 
as well as neutrophilic inflammation. These findings could, after replication and 
validation, contribute to early identification of these patients and thus early initiation 
of causal therapeutic approaches such as allergen immunotherapy. 
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5.1.3.2 Findings for late-onset multitrigger wheeze 
 
Figure 41: Overview of the significant findings for persistent viral wheeze, based on differences in Ct 
values. HC healthy controls, TEV transient early viral wheeze, PV persistent viral wheeze, PM persistent 
multitrigger, LOM late-onset multitrigger, MT multitrigger. Red background marks higher expression, 
green background marks lower expression. All subgroups indicated in the grey boxes have been 
compared to late-onset multitrigger wheeze. * trend like results (p ≤ 0,1); ** significant results (p ≤ 0,05). 
Stimulating conditions can be seen next to the level of significance: 1 unstimulated, 2 
phytohemagglutinin, 3 lipid A. For a detailed legend see chapter 9.5 in the appendix. 
In this in-depth analysis, late-onset multitrigger wheeze, in contrast to persistent 
multitrigger wheeze, only begins after the age of three but shares the classical 
clinical characteristics of multitrigger wheeze, like the occurring of wheeze after 
multiple triggers including but not limited to viral infection. Parallel to in-depth 
analysis of PM wheeze discussed in the previous paragraphs, the main limitation for 
the interpretation of the results for LOM wheeze lies in the small sample size of n=8.  
Nevertheless, a main finding from this work is that instead of sharing a gene 
expression signature with PM wheeze, late-onset multitrigger wheeze shares 
strikingly similar patterns of gene expression with persistent viral wheeze. 
All effects differentiating LOM wheeze from PM wheeze were of special interest. 
LOM wheeze showed lower expression of CALM2, ITPR2, ORAI1, ATP2A3, S100A9, 
IPS1, CD209 and LY75. This was mainly observed after microbial stimulation with 
LpA, but some effects were also visible after mitogen stimulation with PHA such as 
for LY75 and CALM2.  
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Despite the similarities through lower gene expression levels than PM wheeze, 
several trends and significant effects indicate differences between the late-onset 
multitrigger and the persistent viral wheeze group mainly through higher expression 
of the respective genes in LOM wheeze. This includes ITPR2, STIM2, ORMDL3 and 
LY75. On the other hand, LOM vs. PV showed a trend for lowered expression of the 
potentially anti-inflammatory S100A8 after LpA stimulation in the late-onset 
multitrigger group. Effects visible for LOM in comparison to PV wheeze are mimicked 
in effects for late-onset multitrigger wheeze in comparison to healthy controls, visible 
for ITPR2, STIM2, LY75 and S100A8. As both the differences from persistent viral 
wheeze and from healthy controls were found in unstimulated cells, this could 
potentially imply a higher baseline expression of these candidate genes as 
contributing factor to the phenotypic differences. 
 
The phenotype of late-onset wheeze has been connected to a phenotype of 
recurrent, unremitting multitrigger wheeze, matching the definition of LOM in this 
work. This group was characterised by atopy, impaired lung function and varying 
association with smoke exposure in utero [17, 171, 180]. Late-onset multitrigger 
wheeze patients are distinguishable through lung function and prognosis from 
children who start to wheeze before age three, supporting existence of a distinct 
phenotype with separate pathophysiological mechanisms [172]. Findings from this 
work, while to be interpreted with caution, point in the same direction through several 
differences in gene expression of the candidate genes between persistent and late-
onset multitrigger wheeze as summarized above.  
 
The rapid rise in asthma prevalence over the last century highlights the importance of 
environmental influences such as viral infection [188]. Recent studies propose gene-
environment interactions as important for the pathogenesis of childhood asthma, 
especially interesting for LOM wheeze in a two-hit hypothesis. A first hit, respiratory 
viral infection, and a second hit, atopic sensitization, interact to create airway 
inflammation through activation of innate and adaptive immunity and subsequent 
wheeze and childhood asthma [187, 227, 241]. As the late-onset multitrigger wheeze 
subgroup in this work had a genetic signature similar to that of persistent viral 
wheeze, it seems plausible they might also share the susceptibility to viral infection, 
especially as many similarities can be found antiviral innate immunity genes such as 
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IPS1, CD209 and FPR2.  Multitrigger wheeze in general is strongly linked to atopy as 
it has been discussed above, and late-onset multitrigger wheeze is no exception, 
rendering atopic sensitization as a second hit likely. Children with both hits have 
been shown to have a very high risk for persistent asthma and have even been 
labelled as “true asthmatics” in the Tucson birth cohort, a landmark study [12, 186, 
192].  
 
The mechanisms through which viral respiratory infections can contribute to wheeze 
pathogenesis have already been discussed above for persistent viral wheeze and 
could also apply to late-onset multitrigger wheeze. Additionally, it has recently been 
proposed that RV infection as well as allergic inflammation lead to the production of 
IL33, a cytokine important in innate immunity that leads to a Th2 shift. In children with 
difficult to control steroid resistant asthma, an upregulation in the IL33-pathway has 
been identified, while IL33 polymorphisms have been associated with late-onset 
wheeze, in an interesting interface between viral infection and allergic sensitization 
[227, 242, 243]. While these findings see respiratory infection contributing to allergic 
sensitization, allergic sensitization has been shown to impair antiviral (and 
antibacterial) defenses which could lead into a possible vicious circle [244]. 
Especially patients with allergic asthma suffer from impaired innate immunity that 
leaves them prone to viral infections, shown through impaired response to rhinovirus 
in PBMCs of allergic asthmatics [245]. The exact mechanisms of interaction between 
viral infection and aeroallergen sensitization are yet to be completely understood, but 
hypotheses include a cumulative airway damage as well as a higher 
immunopathogenic capacity for pre-existing aeroallergen sensitization in children 
with higher susceptibility for viral infection [186]. Some studies go as far as to 
suggest a causal relationship between rhinovirus induced wheeze and allergy 
development [246]. 
 
However, persistent multitrigger wheeze is also connected to atopy and aeroallergen 
sensitization, yet this phenotype is clearly different from LOM, through longitudinal 
pattern as well as in transcriptional signature as illustrated in fig. 39 and 41.  
Explaining this in a way that is compatible with the other results from this work, 
studies that suggest a redefinition of the term atopy, moving on from a yes/no 
dichotomy to a five-class approach. This sees both PM and LOM as atopy related, 
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with the difference in transcriptional signatures due to different kinds of atopy [241]. 
This approach stresses the importance of the pattern of atopic response (meaning 
age at development as well as type and number of specific allergens) over the simple 
dichotomy. As already discussed, multiple early sensitization has been proposed to 
predict persistent asthma, while for LOM an association with grass pollen 
sensitization has been shown, suggesting the influence of a seasonal allergen as 
possible atopic class for this phenotype [247, 248]. In this study, an analysis of the 
pattern of atopic response was not possible due to limited sample size. However, this 
would be desirable information when validating these data in a larger cohort. 
 
Differentiating late-onset multitrigger wheeze patients from patients with persistent 
multitrigger wheeze as early as possible could result in therapeutic consequences.  
Multiple studies have investigated the reasons for poor response to ICS therapy in 
children with asthma, agreeing that different underlying pathogenetic mechanism are 
a main problem. The gene expression signature for late-onset multitrigger wheeze 
found in this work indicates that this could indeed be a distinct endotype with 
potential pathogenetic similarities to persistent viral wheeze. Thus, after further 
investigation of this theory and careful validation, the results of this work could 
contribute to improving disease management. Given the transcriptional signature, 
children with LOM wheeze are likely to benefit from intermittent ICS therapy that has 
been proposed to alleviate viral wheeze rather than the continuous ICS treatment 
that is currently used for patients with multitrigger wheeze [205, 249-251]. 
Additionally, using non-pharmacological treatment options like trigger avoidance and 
prevention of viral infection that are often underestimated could be very valuable if 
the pathogenetic mechanisms of LOM indeed prove to be more similar to persistent 
viral wheeze [169, 252]. 
 
In summary, results from this work indicate late-onset multitrigger wheeze as a 
separate endotype through the existence of a transcriptional phenotype distinctly 
different from persistent multitrigger wheeze despite similar clinical presentation and 
significant despite low case numbers, with a possibility of an equally distinct 
treatment response. A possible pathogenetic hypothesis fitting these results is a two-
hit hypothesis that sees LOM wheeze as the result of environmental influences such 
as viral infection and atopic sensitization [253-256].  
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5.1.3.3 Schematic summary of the main findings 
The data from this work show distinct gene signatures, already visible in cord blood 
at birth, for the wheeze phenotypes of persistent multitrigger wheeze, late-onset 
multitrigger wheeze and persistent viral wheeze. However, despite the significant 
findings, the results from this study need to be interpreted with the relatively small 
sample size in mind. Taken together, these findings add to the growing evidence that 
the heterogenous group childhood asthma actually consists of several endotypes 
with their respective set of pathogenetic properties. 
In the following paragraphs, several hypothetical possibilities regarding the 
pathogenetic properties of the wheeze subgroups analysed in this work will be 
discussed. 
 
 
Figure 42: Schematic summary of figures 39 to 41. Continuous line represents longitudinal course used 
for this work. Dotted line represents hypothetical continuation after the age of six. Boxes indicate 
phenotype as defined for this work next to the respective trajectory. Gene expression levels as measured 
at birth, as shown in fig. 39-41, summarized in coloured boxes below phenotype identification. 
Upregulated, high gene expression represented in red, downregulated, low gene expression represented 
in green. 
 
The pathogenetic pathway predominantly involved in persistent multitrigger wheeze 
seems to be a genetic susceptibility that favors the development of airway 
inflammation through different factors. The findings from this work are consistent with 
this theory as they show a distinct transcriptional signature with elevated expression 
of pro-inflammatory pathways in cord blood, for example in upregulated expression of 
the candidate genes ultimately influencing the activation of the NLRP3-
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Inflammasome. Favouring the hypothesis that PM wheeze is heavily dependent on 
genetic influences, the CAPPS cohort that followed a high-risk birth cohort of children 
with a family history of asthma and atopy found prevalence rates of up to 21% for 
early persistent (multitrigger) wheeze, two times the prevalence in an average 
population [15, 176]. Additionally, a positive family history of asthma has been 
consistently associated with a higher risk for early onset persistent asthma, a 
definition that is very similar to PM wheeze, as opposed to other wheeze phenotypes 
[257]. However, as genetic susceptibility has been the subject of a multitude of 
studies, it becomes increasingly clear that while it might, for some endotypes such as 
persistent multitrigger wheeze, be the predominant pathogenetic factor, it cannot be 
the only driving pathogenetic mechanism – a theory summarized as “missing 
heritability” [258]. Proposed pathogenetic mechanisms involved include early life 
smoke exposure, however in this study, smoking and smoke exposure could not be 
identified as a confounder [257]. 
For persistent viral wheeze, altered postnatal maturation of the lungs through a lower 
respiratory tract infection with for example rhinovirus is proposed as a possible 
scenario for pathogenetic mechanisms. Additionally, results from this work show a 
transcriptional signature of downregulated expression of the candidate genes 
including antiviral innate immunity and calcium signalling, whose relevance for the IL-
1-pathway has already been discussed above. Thus they seem to be consistent 
with a hypothesis proposed by others that children with persistent viral wheeze have 
a higher susceptibility to viral infection [193].  
 
Other results from our group show increased expression of ATP2A3 and ORMDL3 in 
asthmatic children vs. healthy controls, independent of their atopic status. However, 
results from this work indicate different expression between PV, PM and LOM. A 
possible explanation could be that atopy plays a role in all these children albeit with 
different stress on the role of atopy for each phenotype [77]. This exemplarily shows 
that while multitrigger and viral wheeze are phenotypes that are clear-cut at the 
extremes of their longitudinal manifestations, as for example in this work, their 
persistent forms, but apart from that, they show a considerable overlap. The findings 
for late-onset multitrigger wheeze presented in this work could be a first step towards 
further understanding of this overlap [14].  
 92 
A possible theory for late-onset multitrigger wheeze pathogenesis could be a two-hit 
hypothesis as previously discussed [192]. In summary, this hypothesis sees the 
pathogenesis of late-onset multitrigger wheeze as an overlap between atopy and 
viral infection, with gene-environment interactions as potential mechanism [38, 253]. 
The results from this study show LOM wheeze as an overlap as well, with shared 
clinical characteristics of PM wheeze on one hand, and a similar gene expression 
signature to PV wheeze on the other. While this needs to be cautiously interpreted 
because of the small sample size, it is strengthened by the fact that others already 
found a lacking production of Th1-cytokines, already visible in cord blood, for children 
with late-onset wheeze [186, 259, 260]. 
 
Despite the evidence that some pathogenetic pathways are involved in several 
wheeze phenotypes, there are points where they can be distinguished. 
Both persistent and late-onset (multitrigger) wheeze were associated with atopy. 
However, lung function loss was more pronounced in children that persistent, early 
allergic sensitization as opposed to later onset of atopy. Additionally, (early) atopic 
sensitization was found to increase the airways’ susceptibility to non-allergenic 
stimuli like house dust [261, 262]. Both findings imply that PM and LOM could for 
example be distinguished through disease severity [172, 248, 263].  
As to the differentiation between late-onset multitrigger and persistent viral wheeze, a 
study investigating severe bronchiolitis found that while children that were 
additionally atopic were more likely to develop recurrent wheeze, children who only 
had severe bronchiolitis also had an increased risk for recurrent wheeze. This also 
supports the existence of distinct pathways leading to (late-onset) multitrigger 
wheeze and (persistent) viral wheeze respectively [191]. 
Possibilities include pathways such as IL13, as it was shown to be associated with 
both atopic and non-atopic asthmatics suggesting a distinct influence maybe through 
direct effect on the airways. Other pathogenetic pathways that have a direct influence 
on the airways separate of atopy might contribute to the clinical differences between 
LOM and PV, or the differences in severity between PM and LOM [264]. 
 
A possible hypothesis that emerges from summarizing all of the above, features two 
of the main known pathogenetic pathways. One of those pathways is genetic 
susceptibility, for example to atopic sensitization and airway inflammation, the other 
 93 
is an altered lung development and function through viral respiratory infection. 
However, recent asthma research, including the results of this work, indicate that a 
simple dichotomy does not account for the multiple wheeze phenotypes that are 
clearly distinguishable through several characteristics, and as shown in this thesis, 
also on a transcriptional level. Instead, a graded model for the influence of these 
pathways seems to do asthma pathogenesis more justice. Applied to the wheeze 
phenotypes used in this work, persistent multitrigger wheeze would seem to be 
predominantly caused by the former, while for persistent viral wheeze, the latter is 
more visible, and late-onset multitrigger wheeze is influenced by both. 
However, this is heavily speculative and further investigation is needed to test this 
hypothesis, for example in a larger cohort. 
 
 94 
5.2 Overview of additional findings 
5.2.1 ORMDL3 and 17q21 
As previously discussed, especially persistent wheeze is characterized through high 
association to the known asthma susceptibility locus 17q21, which codes for 
ORDML3 [17, 265]. In another study cohort from our group investigating asthma 
manifestation in children at school age, ORMDL3 as well as ATP2A3 were 
upregulated, despite ORMDL3 physiologically inhibiting ATP2A3. The same was 
visible in this work for persistent multitrigger wheeze. A possible explanation for this 
might be that ATP2A3 is upregulated to overcome the upregulated inhibition via 
ORDML3 [77]. 
However, findings for ORMDL3 in this work were not as strong as one might have 
expected knowing these results and other studies [35]. Having said that, ORMDL3 
results were inconsistent across different studies, being associated with TEV wheeze 
in some populations but with persistent and intermediate-onset wheeze in other 
which suggests a variety of gene-environment interactions in different populations 
[184, 265, 266]. Another explanation might be that the impact of ORMDL3 has been 
identified as mediating airway hyperreagibility in response to allergic sensitization 
especially in airway epithelium cells. As this work examined gene expression levels 
in cord blood, the true effect of ORMDL3 might only reveal itself through GEI that had 
not yet taken place. Fitting this theory as well as the results from this study, Lluis et 
al. found that ORMDL3 expression was lower in CMBCs than in PBMCs of older 
children, which they hypothesized could be due to ORMDL3 expression being 
dependent on immune maturation [267]. 
Of course, the findings in this work could also be due to genotype influence. In 
general, genotype data were assessed in our laboratory. However, this was not the 
focus of this thesis as a stratified analysis was not possible due to small case 
numbers and resulting power limitations. 
Even so, persistent multitrigger wheeze showed a distinct pattern of elevated gene 
expression, including ORMDL3. This might indicate present, but not predominate 
function of ORMDL3 in neonatal immunity. 
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5.2.2 Arachidonic acid cascade 
Candidate genes influencing different aspects of the arachidonic acid cascade were 
significantly differently expressed between the wheeze subgroups, including FPR2, 
both S100A8 and S100A9, and CD209.  
A pattern that emerged from the in-depth group comparisons was an elevated 
expression of associated genes for persistent multitrigger wheeze (visible for FPR2, 
S100A9, and CD209) and lowered expression for late onset multitrigger wheeze 
(visible for S100A8, S100A9, FPR2 and CD209), in comparison to the other wheeze 
subgroups respectively as it can be seen in the overview figures 39 - 41.  
Recently, the intriguing concept of an arachidonic acid mediated calcium influx as an 
alternative to SOCE has been proposed [268]. As the pattern for SOCE-associated 
calcium signalling and the genes associated with arachidonic acid metabolisms show 
the same expression patterns, the results from this study would support this theory 
However, this can only partially explain the effects observed. A possible explanation 
for the elevated expression in persistent multitrigger wheeze might be the induction 
of S100A8 and S100A9 via IL1β. For late onset multitrigger wheeze, it could be 
possible that lowered expression leads to a dysregulation in the arachidonic acid 
cascade, impairing resolution of airway inflammation after viral infection. In 
accordance, it has been found that therapy with the leukotriene antagonist 
montelukast shows a benefit for children with virally induced wheeze [269]. 
Epidemiological studies show these effects could be influenced by nutrition (namely, 
fish oil and omega-3 fatty acids), potentially already prenatally [270]. 
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5.3 Discussion of limitations and strength 
5.3.1 Study design 
The PAULINA/PAULCHEN study is a birth cohort recruited in the metropolitan area 
of Munich and in rural southern Germany, respectively. Due to the natural prevalence 
of wheeze, and especially multitrigger wheeze, case numbers were limited to n=14 
despite the relatively large cohort of n=200 [15]. Even so, results were strongly 
significant in spite of comparatively low case numbers, indicating powerful effects. 
From today’s point of view, additional information from the questionnaires, for 
example more detailed information about viral infections, or a larger volume of cord 
blood available for additional analyses such as western blotting would have been 
desirable. However, conducting such a large birth cohort with in depth immune 
characterization beyond the performed functional studies was logistically not possible 
[68, 168]. 
 
It has been proposed that the time frame in which the individual risk for wheeze and 
asthma is set is very short, ranging from the prenatal period to just the first few years 
of life. As it is additionally becoming increasingly clear just how much prenatal events 
can shape the immune system and thus influence the development of childhood 
wheeze and asthma, birth cohorts are a well-established setting to study its 
pathogenesis [82, 253]. Early biomarkers are an important key to reduce asthma 
morbidity as harmful influences early in life that track through the whole life of the 
patient affected. Only an early biomarker, prenatal or at birth, can contribute 
minimizing these early in life harmful influences, so we studies transcriptional 
signatures in cord blood at birth [5]. 
This particular birth cohort’s strengths include the strict employment of inclusion and 
exclusion criteria (see chapter 3.2), limiting the influence of possibly distorting factors 
to a minimum. The major strength is the detailed longitudinal characterization of the 
study population detailed questionnaires and high follow-up rates.  
 
5.3.2 Wheeze definition 
The questionnaires used provided detailed information about wheeze symptoms, 
other atopy-related diseases (e.g. allergic rhinoconjuctivitis, atopic dermatitis, etc.), 
medication, and general health status of the child as well as a socioeconomic 
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anamnesis. The use of nearly identical questionnaires in both PAULINA and the 
PAULCHEN enabled a joint analysis of the cohorts.  
Using only a parent-dependent, questionnaire-based follow-up might risk incomplete 
or incorrect reporting of the children’s symptoms. As means of compensation, the 
questionnaire included questions about a doctor’s diagnosis of asthma- or atopy-
related symptoms. A major advantage of the questionnaire follow-up was the high 
follow-up rates10.  
A challenge the epidemiological and the clinical approach of phenotyping share is 
dealing with changes in the clinical picture over time, as the assignment of a clinical 
phenotype tends to change, especially in children [38, 271]. One way to deal with this 
challenge is to view the change as a part of the phenotype, thus defining a trajectory 
for this kind of wheeze, increasing both stability and reliability of the phenotypes. The 
other way is that a change in clinical picture automatically leads to reassignment to 
another, more fitting phenotype, which comes at the cost of little to no stability of 
phenotypes [272]. In the PAULINA/PAULCHEN cohort, a combination of clinical 
wheeze phenotypes (multitrigger and viral) and transition trajectories of the well-
established longitudinal Tucson cohort phenotypes (transient early, persistent and 
late onset) was used, thus increasing both stability and reliability of the results for the 
resulting subgroups investigated [14, 82]. This approach is supported by other 
studies with different methods that validated the wheeze phenotypes used in this 
work as comprehensively review by Belgrave et al. [17, 36, 53, 188, 273].    
5.3.3 Stimulation of cord blood mononuclear cells 
CBMC stimulation with PHA as well as LpA is a method commonly used to mimic the 
effects of natural stimulation of the immune system. Phytohemagglutinin (PHA) is a 
protein from the lectin family, and is a powerful stimulus triggering mitosis specifically 
in T-cells by binding to glykoproteins on the cell’s surface, leading to agglutination 
and proliferation [274]. In contrast, LpA (Lipid A) is the biologically active component 
of bacterial LPS and triggers different effects within the innate immune systems as it 
is a ligand for TLR4 [60, 275]. The effect of stimulation was assessed by fold change, 
the comparison to expression of the candidate genes in unstimulated cells. Non-
significant results indicate that gene expression was not significantly up- or 
 
10 Shown in the appendix (9.7).  
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downregulated after stimulation but do not concern the significance of the following 
comparison of the subgroup’s differences in ΔCt.  
For the investigation of the objectives in this study, these two stimulating conditions 
and the additional information about the baseline expression are ideally suited as 
they representatively model effects in both the adaptive and the innate immune 
system respectively.  
5.3.4 Cytokine measurements 
The candidate genes chosen for this work join in the IL1-pathway as final common 
path11. A logical follow-up question is whether the patterns of gene expression levels 
also continues to cytokine levels. The analysis of cytokine levels is currently 
conducted in additional replication studies by the laboratory and thus not the focus of 
this thesis.  
Even so, Rothers et al. investigated cytokine levels in cord blood directly at birth and 
found that cytokine production in cord blood samples did not show any significant 
relation to asthma outcome. However, other results from their study imply that the 
predictive value of cytokine levels is not fully determined at birth but only develops 
during the first year of life, which underlines the importance of the gene expression 
signatures found in this work [264]. 
 
 
 
11 For overview of the candidate genes see a graphical illustration in the appendix. 
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5.4 Implications 
This study supports a graded model for the pathogenesis of childhood wheeze and 
asthma through the findings for persistent multitrigger, late-onset multitrigger and 
persistent viral wheeze. Especially of interest are the strong findings for late-onset 
multitrigger wheeze despite the limited case numbers hinting that LOM wheeze could 
be the result of pathophysiological mechanisms that are clearly distinguishable from 
those causing persistent multitrigger wheeze despite their similar clinical appearance.  
Steps in this direction showed the longitudinal pattern of late-onset and persistent 
wheeze together with AHR and low lung function in childhood as predictors for 
asthma [276]. Findings that differences in lung function levels at age six track to 
adulthood reinforce the importance of early childhood for asthma pathogenesis and 
disease severity [172, 177]. Consistently, a loss of lung function in children that go on 
to have persistent wheeze disorders has been described for the immediate post-natal 
period [187, 277]. This highlights the fact that in clinical practice, the key to reducing 
overall asthma morbidity will be to improve the prediction of wheeze outcomes (see 
chapter 1.6.) in order to identify children at risk for different types of wheeze as early 
as possible [278].  
However, patients will only truly benefit from early identification if therapeutic options 
are available, which provides for another challenge. 
As previously stated, the main therapeutic strategy currently used is ICS therapy in 
different regimens which, however, cannot prevent progression of early to persistent 
wheeze [279]. Findings like this show ICS therapy is symptomatic rather than causal 
and thus should not unthinkingly be used for prevention in preschool children with 
wheeze. While a higher, earlier and more consistent therapy with ICS might prove 
beneficial to some high-risk patients, this is ethically not feasible as long as this high-
risk group cannot be identified properly [278]. Results from this work differentiating 
persistent multitrigger wheeze as a possible high-risk group could provide means to 
test this therapeutic strategy. 
Early and multiple aeroallergen sensitization seems to be pivotal in the pathogenesis 
of persistent multitrigger wheeze in particular. With allergen immunotherapy as a 
possible, causal therapeutic option, early identification of children at risk for PM 
wheeze could lead to an earlier treatment start, limiting consequential damages. 
Aeroallergen sensitization is also important for the development of LOM wheeze, and 
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early identification of these children could improve asthma prevention through for 
example advising parents to avoid allergens in sensitized children [227, 262, 280].   
Supportingly but not un-controversially discussed, Owara et al. found that the 
wheeze trajectory of early wheeze could be modified by prenatal intervention such as 
the avoidance of house dust, pets, and environmental tobacco smoke and 
encouragement of exclusive breastfeeding [176].  
 
Supporting this work’s approach to early identification, a recent study by Howrylak et 
al. showed a correlation between clinically assigned phenotype and gene expression 
of atopy-related genes, albeit in a cohort of older children. Even so, these findings 
are parallel to what was shown in this work supporting the existence of transcriptional 
signatures for these particular phenotypes [281]. 
In order to be suitable for screening purposes, a candidate gene would have to show 
elevated expression in comparison to ideally all other possible groups, especially 
healthy controls. Based on the results showing that persistent multitrigger wheeze is 
a distinct entity with a specific pattern of gene expression within multitrigger wheeze, 
several candidate genes could be proposed as candidates for further investigation 
through replication and validation with the goal of identifying possible biomarkers for 
persistent multitrigger wheeze. The most promising of these results were seen for 
CALM2 after PHA stimulation. To date, high expression of CALM2 in CBMCs has not 
yet been associated to any other disease than childhood wheeze and asthma.  
It has been shown that a biomarker alone cannot predict a complex disease like 
asthma, but combining different biomarkers largely increases the reliability of such 
predictions [75, 282]. Hence, eventually adding the measurement of CALM2, after 
further testing and validation, to a predictive model that already exists could largely 
increase the predictive value of the tool in question [283]. In addition, a biomarker 
from cord blood would have many advantages as it can be gained non-invasively and 
would predict the risk for wheeze development at the earliest point possible. 
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5.5 Outlook 
Currently, our research group is working on the analysis of further follow-up to both 
the PAULINA and the PAULCHEN cohort, which will provide valuable information 
about the further development of the study population, as for example diagnoses of 
childhood asthma. Naturally, extending the subgroup definition to include the 
phenotypes at 10 years and then again comparing gene expression for the candidate 
genes would be a first validation of the results of this thesis and will be done in due 
course. In order to solve the puzzle that is the pathogenesis of childhood asthma, 
data from cohorts of older children and other groups should be brought together with 
data from birth cohorts so they can complement and complete each other [210]. 
While in this work this was already partly realized in the choosing of the candidate 
genes, our group will continue to do so as new insights are gained. 
 Additional findings from this work warrant further investigation concerning the role of 
the arachidonic acid cascade in asthma pathogenesis that would most likely 
contribute to a further understanding of the pathophysiology of steroid-resistant 
asthma. 
For further validation a birth cohort with adjusted design, as well as a higher number 
of cases, should be recruited. The new design might consider including more 
extensive functional investigation of different subsets of CBMCs. Also, protein 
assessment e.g. by western blot to prove that elevated gene expression also leads to 
elevated protein counts (or lowered, respectively) would be of high interest. 
Ultimately, obtaining blood samples in addition to questionnaires at each follow-up 
would provide the opportunity to study changes in the expression of the candidate 
genes as the immune system matures. 
5.6 Conclusion  
In recent research, it has become clear that asthma is a complex, heterogeneous 
disease with a clear hereditary component. Many pathophysiological pathways have 
been identified. While findings of varied expression in single genes often only 
marginally impacts the asthma phenotype, this study detected a consistent pattern of 
varied gene expression for the calcium-signalling pathway revolving around store-
operated calcium entry (SOCE) in children with different subsets of multitrigger 
wheeze. In particular, findings for late-onset multitrigger wheeze, while keeping in 
mind the small case numbers in this study, reinforce the diversity of mechanisms 
involved in asthma pathogenesis and the need for further endotyping. 
 102 
6 Summary  
Asthma remains one of the most common chronic diseases in childhood, developing 
already early in life. In the first year of life, children start to present with wheeze, 
which is currently classified as multi-trigger or viral-wheeze based on specific triggers 
and their long-term time course. An early prediction of children with wheeze and at 
risk for subsequent asthma is currently difficult and underlying immune mechanisms 
of distinct wheeze phenotypes are unknown.  
As early priming of the immune system occurs already prenatally, we aim to identify 
predictive markers for children at risk for subsequent development of childhood 
wheeze and asthma. From previous work of our research group, innate immune 
regulation, in particular antiviral immunity (LY75, CD209, IPS1) and Ca2+-signalling 
pathways, e.g. CALM2 and genes related to store-operated calcium entry (ITPR2, 
STIM2, ORAI1, ORMDL3 and ATP2A3) have been shown to be differentially 
expressed between asthmatics and healthy children during disease manifestation at 
school-age. Here, we aimed to assess these genes at the earliest time point, namely 
at birth. We investigated gene regulation as potential predictive markers for the 
development of subsequent wheeze phenotypes.  
The mRNA-expression of selected candidate genes of Ca2+-signalling (CALM2, 
ITPR2, ORAI1, STIM2, ORMDL3, ATP2A3) and innate immunity (CD209, LY75, 
FPR2, IPS1) was measured in CBMCs of children with subsequent wheeze 
phenotypes compared to healthy children (HC). Children were selected from the 
PAULINA/PAULCHEN cohort (n=200). Phenotypic classification in multitrigger, 
persistent viral or early viral wheeze and healthy control was based on clinical 
information from questionnaires answered by the parents at age 3 and/or 6 years. 
Previously, cord blood was taken from healthy neonates with strict inclusion criteria, 
and CBMCs were isolated within 24 hours, kept unstimulated or were stimulated with 
PHA or LpA for 72h. Gene expression at mRNA level was assessed via qRT-PCR, 
and analysed with the Wilcoxon rank sum test. 
The following results were obtained and are presented in this thesis: 
1.   Expression of all candidate genes of calcium signalling and viral innate immunity 
was detectable and varied significantly or trend-wise between the different 
wheeze subgroups and healthy controls (mainly ITPR2, CALM2, ORAI1, STIM2, 
FPR2, IPS1, LY75). 
2.   Children with persistent viral wheeze showed a lower expression of the candidate 
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genes (ITPR2, CALM2, ORAI1, STIM2, ATP2A3, IPS1, LY75, CD209) than the 
other wheeze subgroups. 
3. Children with persistent multitrigger wheeze showed a distinct pattern of elevated 
expression for the candidate genes (ITPR2, CALM2, ORAI1, STIM2, ORMDL3, 
ATP2A3, S100A9 FPR2, IPS1, LY75, CD209). This was visible for the whole 
calcium-signalling pathway, supporting the view of persistent multitrigger wheeze 
as distinct entity and suggests a pathophysiological relevance of calcium 
signalling. 
4. Despite parallels in clinical presentation, late-onset multitrigger wheeze share 
gene expression patterns with persistent viral rather than persistent multitrigger 
wheeze, suggesting a different underlying pathophysiology. 
Taken together, these results affirm the emerging view of childhood asthma as a 
complex disease and show that differences in immune regulation are already visible 
at birth. Importantly, especially the findings for persistent multitrigger wheeze could 
eventually, after suitable validation for example in a larger cohort with higher case 
numbers, help in the development of specific biomarkers before disease 
manifestation, which may contribute to closer clinical monitoring and in the long-term 
potentially to a change in therapy for patients with distinct phenotypes of childhood 
asthma. 
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7 Zusammenfassung 
Asthma ist eine der häufigsten chronischen Erkrankungen im Kindesalter und 
entwickelt sich bereits in frühen Lebensjahren. Bereits im ersten Lebensjahr zeigen 
die Kinder wheeze (engl. die typische Asthmasymptomatik Pfeifen und Giemen), das 
zurzeit in Abhängigkeit der jeweiligen Auslöser sowie des longitudinalen Verlaufs 
entweder als multi-trigger wheeze oder viral bedingt klassifiziert wird. Eine frühe 
Identifikation von Kindern mit wheeze und einem erhöhten Risiko, ein daraus 
hervorgehendes Asthma zu entwickeln, ist im Moment schwierig. Die der 
Heterogenität der wheeze-Phänotypen zugrundeliegenden pathophysiologischen 
Mechanismen des Immunsystems sind nur unzureichend bekannt.  
Da das frühe Priming des Immunsytems bereits pränatal stattfindet, war das Ziel 
dieser Arbeit, prädiktive Marker für Kinder mit einem erhöhten Risiko für wheeze und 
Asthma im Kindesalter zu identifizieren. Aus früheren Arbeiten der Arbeitsgruppe ist 
bereits bekannt, dass Gene der Regulation des angeborenen Immunsystems, vor 
allem im Bereich der antiviralen Abwehr (z.B. LY75, CD209, IPS-1) und des Calcium-
Signalweges (z.B. CALM2) sowie der SOCE (store-operated calcium entry) (z.B. 
ITPR2, STIM2, ORAI1, ORMDL3 und ATP2A3) bei asthmatischen und gesunden 
Kindern während der Manifestationsphase der Erkrankung unterschiedlich hoch 
exprimiert werden. Im Folgenden soll die Expression dieser Gene zum 
frühestmöglichen Zeitpunkt, also bei Geburt, analysiert werden. Die Genexpression 
soll im Hinblick auf eine mögliche Verwendung als prädiktive Marker für die 
Entwicklung bestimmter wheeze-Phänotypen untersucht werden. 
Die Expression von mRNA der ausgewählten Kandidatengene des Calciu-
Signalweges (CALM2, ITPR2, ORAI1, STIM2, ORMDL3, ATP2A3) und des 
angeborenen Immunsystems (CD209, LY75, FPR2, IPS1) wurde in CBMCs 
gemessen. Im Anschluss wurde die Genexpression von Kindern mit durch Follow-Up 
Untersuchungen bekanntem wheeze mit der Genexpression von pulmonal gesunden 
Kindern (healthy controls, HC) verglichen. Die Kinder wurden aus der 
PAULINA/PAULCHEN-Geburtskohorte (n=200) ausgewählt. Von den in die 
Geburtskohorte eingeschlossen, gesunden Neugeborenen wurde Nabelschnurblut 
gewonnen. Daraus wurden innerhalb von 24h CBMCs (cord blood mononuclear 
cells) isoliert, die dann entweder unstimuliert belassen oder mit PHA bzw. LpA 
stimuliert wurden. Die Einteilung in die unterschiedlichen wheeze-Phänotypen  
„multitrigger wheeze“ (durch mehrere Faktoren ausgelöst), „persistent viral wheeze“ 
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(persistierende Symptome, die durch virale Infektionen ausgelöst werden) und 
„transient early wheeze“ (frühe Symptome, die durch virale Infektionen ausgelöst 
werden und vorübergehend sind) sowie in die gesunde Kontrollgruppe erfolgte 
anhand der klinischen Informationen aus Fragebögen, die im Alter von 3 und/oder 6 
Jahren von den Eltern ausgefüllt wurden. Die Genexpression wurde auf mRNA-Level 
durch qRT-PCR untersucht und mit dem „Wilcoxon rank sum“-Test statistisch 
analysiert.  
Die folgenden Ergebnisse wurden erzielt und in dieser Doktorarbeit vorgestellt: 
1. Die Expression von Kandidatengenen des Calciumsignalweges und der 
angeborenen, antiviralen Immunität war nachweisbar und zeigte sich 
signifikant oder als Trend unterschiedlich zwischen den unterschiedlichen 
wheeze-Gruppen sowie im Vergleich mit den gesunden Kontrollen (vor allem 
für ITPR2, CALM2, ORAI1, STIM2, FPR2, IPS1 und LY75). 
2. Kinder mit „persistent viral wheeze“ zeigten eine niedrigere Expression der 
Kandidatengene (ITPR2, CALM2, ORAI1, STIM2, ATP2A3, IPS1, LY75, 
CD209) als die anderen Wheeze-Untergruppen, besonders nach Stimulation 
mit LpA. 
3. Kinder mit „persistent multitrigger wheeze“ (durchgängig durch mehrere 
Mechanismen ausgelöst) zeigten ein abgegrenztes, charakteristisches Muster 
einer erhöhten Genexpression der Kandidatengene (ITPR2, CALM2, ORAI1, 
STIM2, ATP2A3, S100A9, FPR2, IPS1, LY75, CD209), vor allem nach 
Stimulation der CBMCs mit PHA. Dieses Muster war für den gesamten 
Calciumsignalweg sichtbar. Dies stützt die Theorie, nach der „persistent 
multitrigger wheeze“ eine eigene, scharf abgegrenzte Entität darstellt, 
möglicherweise pathophysiologisch vermittelt durch Veränderungen im 
Calciumsignalweg. 
4. Trotz der klinischen Zuordnung beider Gruppen als „multitrigger wheeze“ zeigt 
„late onset multitrigger wheeze“ (spät einsetzend, durch mehrere Faktoren 
ausgelöst) in der Genexpression der Kandidatengene kaum Ähnlichkeiten mit 
„persistent multitrigger wheeze“. Stattdessen finden sich auffällige Parallelen 
zu den Genexpressionsmustern von „persistent viral wheeze“, was einen 
unterschiedlichen pathogenetischen Mechanismus für die beiden 
Untergruppen von „multitrigger wheeze“ nahelegt.  
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Zusammen bekräftigen diese Ergebnisse, dass Asthma als eine komplexe 
Krankheit anzusehen ist und dass Veränderungen in der Immunregulation bereits 
bei Geburt sichtbar sind. Besonders die Erkenntnisse über „persistent multitrigger 
wheeze“ könnten eventuell, nach entsprechender Validierung z.B. in einer 
Kohorte mit größeren Fallzahlen, für das Fernziel der Entwicklung spezifischer 
Biomarker, die bereits vor der Manifestation der Krankheit verwendbar sind, von 
Interesse sein. Ein Vorteil, der sich daraus für Kinder mit Asthma ergeben könnte, 
wäre eine engmaschigere klinische Kontrolle und vielleicht als Fernziel eine 
Anpassung der Therapiestrategien an den jeweiligen Phänotyp. 
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9 Appendix 
9.1 Abbreviations 
AHR 
Airway hyper 
responsiveness 
GWAS 
Genome wide 
association studies 
PAULCHEN 
Prospective Cord 
Blood Study in 
Rural Southern 
Germany 
(m)API 
(Modified) asthma 
predictive index 
HC Healthy control PAULINA 
Pediatric Alliance 
For Unselected 
Longitudinal 
Investigation of 
Neonates for 
Allergy 
(qRT-
)PCR 
Quantitative Real-Time 
Polymerase Chain 
Reaction 
HDM house-dust mite PBMC 
peripheral blood 
mononuclear cells 
[Ca2+]e 
Concentration of 
extracellular calcium 
ICS 
Inhalative 
corticosteroid 
PG prostaglandine 
[Ca2+]i 
Concentration of 
intracellular calcium 
IFN Interferon PGE2 prostaglandin E2 
AERD 
Aspirin-exacerbated 
respiratory disease 
IgE Immunoglobulin E PHA phytohemagglutinin 
APC antigen presenting cells IL interleukin PLC phospholipase C 
ASC 
Apoptosis-associated 
speck-like protein 
containing a CARD 
IP3 inositoltriphosphate PM 
Persistent 
multitrigger wheeze 
ATP Adenosine triphosphate IPS1 
Synonym for 
Mitochondrial 
antiviral-signalling 
protein 
PRR 
Pattern 
Recognition 
Receptor 
ATP2A3 
ATPase 
Sarcoplasmic/Endoplasmic 
Reticulum Ca2+ 
Transporting 3 
ITPR2 
Inositol 1,4,5-
trisphosphate 
receptor, type 2 
PV 
Persistent viral 
wheeze 
Ca2+ Calcium LCA 
Latent Class 
Analysis 
RAST 
radio-allergo-
sorbent test 
CALM2 Calmodulin 2 LOM 
Late-onset 
multitrigger wheeze 
RLR RIG-I-like receptors 
CALMKII 
calmodulin-dependent 
kinase II 
LpA LipidA ROS 
Reactive oxygen 
species 
cAMP 
cyclic adenosine 
monophosphate 
LT leukotriene S100A8 
S100 calcium 
binding protein A8 
Casp1 Caspase 1 LY75 
Lymphocyte 
antigen 75 
S100A9 
S100 calcium 
binding protein A9 
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CBMC 
Cord blood mononuclear 
cells 
MAPK 
mitogen-activated 
protein kinase 
SERCA 
sarco-
endoplasmatic 
reticulum Ca2+ - 
ATPase 
CD209 
Cluster of Differentiation 
209 
MHC 
Major 
Histocompatibility 
Complex 
SNP 
single nucleotide 
polymorphisms 
CLR C-Type Lectin receptors miRNA Micro-RNA SOCE 
Store-operated 
calcium entry 
COPD 
Chronic obstructive 
pulmonary disease 
mRNA Messenger-RNA STIM1 
Stromal interaction 
molecule 1 
CRAC 
Calcium release-activated 
channels 
MT Multitrigger wheeze STIM2 
Stromal interaction 
molecule 2 
Ct Cycle of threshold NFAT 
nuclear factor of 
activated T-cells 
TCR T-cell receptor 
DAMP 
damage-associated 
molecular patterns 
NFκB 
nuclear factor 
'kappa-light-chain-
enhancer' 
TEV 
Transient early 
viral wheeze 
DC Dendritic cells NK Natural killer cells Th-cells T-helper-cells 
DDX58 DEXD/H-Box Helicase 58 NLR Node-like receptors TLR Toll-Like receptors 
DHX58 DEXH-Box Helicase 58 NLRP3 
NACHT, LRR and 
PYD domains-
containing protein 
3 
Treg Regulatory T-cells 
EC Epithelial cells ORAI1 
Calcium release-
activated calcium 
channel protein 1 
UFR 
Unfolded protein 
response 
ER Endoplasmatic reticulum ORMDL3 
orosomucoid 1-like 
protein 3 
VM 
Viral to multitrigger 
wheeze 
FPR2 
N-formyl peptide receptor 
2 
PAMP 
pathogen 
associated 
molecular patterns 
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9.3 Register of tables 
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9.4 Primer sequences 
Candidate 
gene 
Forward sequence 
 
Reverse sequence 
(complementary) 
 
ATP2A3 GCTGGCTCTTCTTCCGATACCTG TTTCAATGGTCACGAGCACGG 
CALM2 GATGGCAAGAAAAATGAAAGACAC ACCATCACCATCAATATCTGCTTC 
CD209 GCTCGTCGTAATCAAAAGTGCTG CATTTGTCGTCGTTCCAGCC 
FPR2 CTCCACTCCTCTGAATGAATATGAAG ATGGAGACAATGAGGAATGGTAATG 
IPS1 GCAGAGAGAAGGAGCCAAGTTACCC TTCTGTGTCCTGCTCCTGATGCC 
ITPR2 TCGGTCAACGGCTTCATCAG GGTTCCCTTGTTTGGCTTGC 
LY75 GAAGAAGCATCCCCTAAGCCTG AAACCAATCCACAGCCAATGC 
ORAI1 GCACAATCTCAACTCGGTCAAGG GTGGACGGCGAAGACGATAAAG 
ORMDL3 GGACCAGGGCAAGGCGAG CACGCTCATCAGGGACACGG  
S100A8 GGGATGACCTGAAGAAATTGCTAG CTACTCTTTGTGGCTTTCTTCATGG 
S100A9 GAACGCAACATAGAGACCATCATC GCATGATGAACTCCTCGAAGC 
STIM2 GCCTGACCTCTTCCCTTTATTCTG GGCTGCTGCTTCTGGCTAATG 
18S AGTCCCTGCCCTTTGTACACA GATCCGAGGGCCTCACTAAAC 
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9.5 Gene overview map 
 
 
Schematic overview of a cell ( light grey background).  
 Genes associated to 
calcium signalling 
 Inhibiting influence 
 Genes associated to 
innate signalling 
 
Gene or respective protein 
 Activating influence  Second messenger 
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9.6 Questionnaires 
9.6.1 PAULINA at inclusion  
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9.6.2 PAULINA three year follow-up 
  
  
Befragten-ID:
Interviewer-ID:
Datum des Ausfüllens
/ / 
Tag/ Monat/ Jahr
Beginn des Interviews (Uhrzeit):
/ 
Std / Min
2
Mit wem wurde das Interview durchgeführt?
Mutter.....................................................¨
Vater ......................................................¨
Andere: .¨
Wie wurde der Fragebogen ausgefüllt?
Persönlich..............................................¨
Telefonisch ............................................¨
Selbstausfüller .......................................¨
3
F Vor Beginn des Interviews bitte inhaltlich wiedergeben
• Begrüßung
• Dauer des Interviews (ca. 30 min) erläutern
• Erläuterung des Interviewablaufs
Die meisten Fragen können mit Ja/ Nein beantwortet werden  
Bei einigen Fragen gibt es andere Antwortmöglichkeiten
Bitte Fragen erst beantworten, nachdem sie vollständig vorgelesen wurden  
Bei Antworten bitte immer den gesamten Wortlaut der zutreffenden
Antwortkategorie vorlesen
Bei Verständnisproblemen bitte reagieren
• Hinweis, dass nun das Interview mit einigen Fragen zur Gesundheit des Kindes  
beginnt.
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4. Wodurch wurden bei Ihrem Kind die pfeifenden / keuchenden  
Atemgeräusche ausgelöst?
Ja Nein  
Anstrengung .................................. ¨ ..........¨
Erkältung........................................ ¨ ..........¨
Kontakt mit Tieren.......................... ¨ ..........¨
Kontakt mit Hausstaub................... ¨ ..........¨
Kontakt mit Gras............................ ¨ ..........¨
Sonstiges:
.... ¨ ..........¨
5. Hat Ihr Kind jemals in den letzten 3 Jahren von einem Arzt Medikamente  
gegen pfeifende oder keuchende Atemgeräusche verschrieben  
bekommen?
(Gemeint sind damit nicht nur Medikamente zum Schlucken, sondern auch  
Inhalationen oder Sprays)
Ja ................¨
Nein.............¨ Þ weiter mit Frage 8!
6. Welche Medikamente waren dies?
Bitte notieren Sie jeweils möglichst genau den Markennamen.
1. 
2. 
3. 
7. Erhält Ihr Kind solche Medikamente gegen pfeifende oder keuchende  
Atemgeräusche
nur bei besonders schweren Phasen solcher Atemgeräusche? .....................
¨ bei (fast) jeder Phase pfeifender oder keuchender Atemgeräusche?
................ ¨ sowohl während akuter Phasen derartiger Geräusche als auch
vorbeugend? ¨
8. Wurde bei Ihrem Kind jemals von einem Arzt ein Allergietest durchgeführt?
Ja Nein  
Ein Hauttest........................................ ¨ ..........¨
Ein Bluttest .........................................¨ ..........¨
Ein anderer Test, z.B. Bioresonanz ... ¨ ..........¨
F Achtung
Wenn alle drei Test-Arten mit „Nein“ beantwortet wurden, weiter mit Frage  
10!
9. Welche Allergie wurde dabei festgestellt?
Ja Nein  
Gegen Pollen................................. ¨ ..........¨
Gegen Hausstaub(milben)............. ¨ ..........¨
Gegen Tiere................................... ¨ ..........¨
Gegen Nahrungsmittel................... ¨ ..........¨
Andere:
.... ¨ ..........¨
6
7
Es folgen Fragen zu Hauterkrankungen
10. Hatte Ihr Kind jemals in den letzten 3 Jahren einen juckenden  
Hautausschlag mit Kratzen und Reiben der Haut?
Ja ................¨
Nein.............¨ Þ weiter mit Frage 15!
11. War der Hautausschlag in den letzten 3 Jahren je an einer der folgenden  
Stellen? Ja Nein
Gesicht........................................... ¨ ..........¨
Hals................................................ ¨ ..........¨
Ellenbeugen / Kniekehlen.............. ¨ ..........¨
Hand- / Fußgelenke....................... ¨ ..........¨
12. Wenn Sie die Zeiten, in denen Ihr Kind diesen Hautausschlag hatte,  
zusammen zählen: Wie lange haben Sie in den letzten 3 Jahren diesen  
Hautausschlag jeweils pro Jahr beobachtet?
Für insgesamt weniger als 6 Wochen / Jahr ¨
Für insgesamt 6 Wochen bis 2 Monate/ Jahr ¨
Für insgesamt 3-5 Monate/ Jahr............
¨
Für insgesamt 6-11 Monate/ Jahr..........
¨
Praktisch für die gesamten 12 Monate/ Jahr ¨
Þ weiter mit Frage 15!
13. Ist der Hautausschlag wieder völlig verschwunden, oder „kommt und geht“  
der Hautausschlag?
Der Hautausschlag ist vollständig  
verschwunden........................................¨
Der Hautausschlag „kommt und geht“ ...¨
Der Hautausschlag ist noch da..............¨ Þ weiter mit Frage 15!
8
14. Wie alt war Ihr Kind, als der Hautausschlag wieder vollständig  
verschwunden ist?
Monate
Þ weiter mit Frage 19!
15. Wie häufig kam es in den letzten 3 Jahren vor, dass ihr Kind sich kratzt?
Nie .........................................................¨
Seltener als einmal pro Monat ...............¨
1 bis 3 mal pro Monat ............................¨
4 bis 6 mal pro Woche...........................¨
Ein- oder mehrmals täglich ....................¨
16. Wie häufig kam es in den letzten 3 Jahren vor, dass Ihr Kind sich wegen  
eines starken Juckreizes blutig gekratzt hat?
Nie .........................................................¨
Seltener als einmal pro Monat ...............¨
1 bis 3 mal pro Monat ............................¨
4 bis 6 mal pro Woche...........................¨
Ein- oder mehrmals täglich ....................¨
17. Wie häufig ist Ihr Kind in den letzten 3 Jahren nachts wegen Juckreiz  
aufgewacht?
Seltener als einmal pro Monat ...............¨
Einmal pro Monat...................................¨
Mindestens zweimal pro Monat .............¨
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18. Haben Sie die Haut Ihres Kindes in den letzten 3 Jahren mit einer  
cortisonhaltigen Creme / Salbe oder einer Tacrolimus- bzw. Pimecrolimus-
haltigen Salbe (Protopic, Elidel) behandelt?
Ja ................¨
Nein.............¨
Es folgen Fragen zu anderen Erkrankungen
19. Wurde bei Ihrem Kind in den letzten 3 Jahren von einem Arzt/einer Ärztin 
eine spastische Bronchitis, obstruktive Bronchitis oder asthmatische  
Bronchitis diagnostiziert?
Nein, nie......................................¨
Ja, einmal....................................¨
Ja, mehrmals...............................¨
20. Wurde bei Ihrem Kind in den letzten 3 Jahren von einem Arzt/einer Ärztin 
eine der folgenden Diagnosen gestellt?
Ja Nein  
Asthma........................................... ¨ ..........¨
Neurodermitis, atopische Dermatitis
oder endogenes Ekzem................. ¨ ..........¨
Es folgen Fragen zu Nahrungsunverträglichkeiten oder -allergien
21. Reagiert Ihr Kind auf irgendwelche Nahrungsmittel mit 
Hautveränderungen? Wir meinen damit eine Nesselsucht oder das  
Auftreten bzw. die Verschlechterung einer Neurodermitis.
Ja ................¨
Nein.............¨ Þ weiter mit Frage 25!
22. Auf welche Nahrungsmittel reagiert Ihr Kind mit derartigen 
Hautveränderungen?
Ja Nein  
Milch und Milchprodukte..............................................¨ ......¨
Hühnereier...................................................................¨ ......¨
Fisch............................................................................¨ ......¨
Weizenmehl oder andere Getreideprodukte ...............¨ ......¨
Nüsse ..........................................................................¨......¨
Soja .............................................................................¨ ......¨
Zitrusfrüchte ................................................................¨ ......¨
Anderes Obst oder Gemüse........................................¨ ......¨
Andere Nahrungsmittel................................................¨ ......¨
Welche? 
23. Wurde bei Ihrem Kind von einem Arzt / einer Ärztin in den letzten 3 Jahren  
eine Nahrungsmittelallergie diagnostiziert?
Ja ................¨
Nein.............¨
10
Þ weiter mit Frage 25!
24. Wurde diese Nahrungsmittelallergie durch einen Allergietest bestätigt?
Ja Nein
Durch einen Hauttest, einen Bluttest oder
einen oralen Provokationstest ....................................¨ ...... ¨
Durch einen anderen Test, z.B. Bioresonanz ..............¨ ......¨
Nun haben wir die Fragen zur Gesundheit Ihres Kindes  
abgeschlossen.
Es geht nun um seine Ernährung, dann um die Umgebung.
25. A) Haben Sie Ihr Kind gestillt?
Ja  
Nein
¨ Wie lange haben Sie Ihr Kind gestillt?.............................
¨
Angaben zur Wohnungs- und Lebenssituation
26. A) Wie viele jüngere Geschwister hat Ihr Kind?
Bitte auch Stiefgeschwister mitzählen, die in Ihrer Familie leben!  
Schwestern.......................Stiefschwestern................
Brüder...............................Stiefbrüder........................
B) Wie viele ältere Geschwister hat Ihr Kind?
Bitte auch Stiefgeschwister mitzählen, die in Ihrer Familie leben!
Schwestern.......................Stiefschwestern...............  
Brüder...............................Stiefbrüder........................
11
27. Bitte notieren Sie Name und Geburtsdatum der Geschwister Ihres Kindes.
Bitte auch Stiefgeschwister mitzählen, die in Ihrer Familie leben!
Name Mädchen Junge Geburtsdatum
¨ ¨ / /
¨ ¨ / /
¨ ¨ / /
28. Wird Ihr Kind regelmäßig zusammen mit anderen Kindern betreut (z.B.  
durch eine Tagesmutter, in einer Kinderkrippe oder bei den Großeltern)? Die  
eigenen Geschwister sind dabei nicht gemeint.
Ja, ..........................................................¨
Mit wie vielen anderen Kindern?
Nein .......................................................¨
29. Welche der folgenden Haustiere haben/hatten Sie innerhalb der Wohnung ?
(Mehrere Antworten sind möglich)
Zur Zeit Im 1. oder 2. Lebensjahr
Hund ¨...............................¨
Katze ¨...............................¨
Hamster ¨...............................¨
Meerschweinchen ¨...............................¨
Kaninchen ¨...............................¨
Vögel ¨...............................¨
Aquarium (Fische) ¨...............................¨
12
 132 
  
 
 
 
 
13
A) Darf oder durfte sich eine Katze im Zimmer, in dem Ihr Kind schläft
aufhalten?
Ja ¨
Nein ¨
B) Darf oder durfte sich eine Katze im Bett Ihres Kindes aufhalten?
Ja ¨
Nein ¨
C) Darf oder durfte sich ein Hund im Zimmer, in dem Ihr Kind schläft  
aufhalten?
Ja ¨
Nein ¨
D) Darf oder durfte sich ein Hund im Bett Ihres Kindes aufhalten?
Ja ¨
Nein ¨
30. Hat/hatte Ihr Kind sonst regelmäßig (ca. 1x/Woche) Kontakt zu folgenden  
Tieren (z.B. in der Wohnung von Freunden/ Verwandten, Käfig/Stall  
außerhalb der Wohnung)?
(Mehrere Antworten sind möglich)
Zur Zeit Im 1. oder 2. Lebensjahr
Hund ¨...............................¨
Katze ¨...............................¨
Pferde ¨...............................¨
Es folgen Fragen zum Rauchverhalten
31. Haben Sie und Ihre Familie in den letzten 3 Jahren mit dem Rauchen in der  
Wohnung aufgehört bzw. das Rauchen innerhalb der Wohnräume  
eingeschränkt?
Ja......................................¨
Nein ..................................¨
Es wurde nie geraucht......¨ Þ weiter mit Frage 33!
32. Wie viele Zigaretten werden durchschnittlich am Tag
in Ihrer Wohnung (damit meinen wir auch die Küche) geraucht?  
Zigaretten, die auf dem Balkon oder der Terrasse geraucht werden,  
brauchen nicht mitgezählt zu werden.
Wie viele davon von... (keine=0)
Mutter pro Tag
Partner pro Tag
Andere Personen pro Tag
Insgesamt pro Tag
Þ Bitte neue Adresse notieren!
14
33. Sind Sie in den letzten 3 Jahren (d.h. seit das Kind geboren wurde)  
umgezogen?
Ja ............................¨
Nein.........................¨
Haben Sie noch weitere Kommentare zum Fragebogen oder allgemein?
Wir danken Ihnen herzlich für das  
Ausfüllen des Fragebogens!
15
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9.6.3 PAULINA six year follow-up 
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9.6.4 PAULCHEN at inclusion 
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9.6.5 PAULCHEN three-year follow-up 
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9.6.6 PAULCHEN six-year follow-up 
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9.7 Follow-up rates 
Cohort   
PAULINA 3 year follow-up 88.9% 
PAULINA 3 year follow-up 84.4% 
PAULCHEN 6 year follow-up 91.2% 
PAULCHEN 6 year follow-up 89.01% 
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